Molecular and Immunological Analyses of 38 kDA and 45 kDA Protein Antigens of Pasteurella Haemolytica S1 by Pandher, Karamjeet
MOLECULAR AND IMMUNOLOGICAL ANALYSES 
OF 38 kDAAND 45 kDA PROTEIN ANTIGENS 
OF Pasteurella haemolytica Sl 
By 
KARAMJEET PANDHER 
Bachelor of Veterinary Science 
College of Veterinary Sciences 
Punjab Agricultural University 
Punjab, India 
1993 
SubmiUed to the Faculty of the 
Graduate College of 
Oklahoma State University 
in partial fulfillment of · 
the requirements for 
the Degree of 





MOLECULAR AND IMMUNOLOGICAL ANALYSES 
OF 38 kDA AND 45 kDA PROTEIN ANTIGENS 
OF Pasteurella haemolytica Sl 
II 
· ACKNOWLEDGMENTS 
I would like to thank my major advisor, Dr. George L. Murphy for his 
constant guidance, instruction and constructive criticism, without which this 
research would not have been possible. I also appreciate his effort and 
patience in teaching me the techniques involved in molecular biology and 
technical writing. I would like to express my gratitude to the members of my 
advisory committee Drs. K.D. Clinkenbeard, A.W. Confer, and J.H. Wyckoff 
. whose suggestions, guidance, and support Were. extremely helpful. I would 
especially like to thank Dr. A.W. Confer for providing me with sera used in 
my research and also for helping with statistical analysis of the data. Thanks · 
are also due to Drs. R.E. Eberle, C.W. Qualls, R.J. Panciera and S. Sangiah for 
their constant encouragement and support. 
I would like to acknowledge my family for their love, moral and financial 
support during my years as a student. They have always encouraged me to go 
the extra mile. My years in Stillwater and Oklahoma State University were 
extremely pleasant ones, because of friends with whom I was fortunate 
enough to share my time and thoughts. 
Finally, I would like to thank the College of Veterinary Medicine for 
supporting me on a research assistantship through these five years of study. 
iii 
TABLE OF CONTENTS 
Chapter Page 
I. INTRODUCTION . 1 
Pathogenesis . . . . . · . . . . . . . . . . . . . . . · . . . . . . . . . . . . . . . . . 3 
Bacterial factors associated with virulence . . . . . . . . . . . . . . . . . . . . 6 
Immu.nological importance of P. haemolytica molecules .......... 10 
Mutational analysis of P. haemolyt.ica molecules ............... 17 
Vaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 
Host defense mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . .23 
Summary and statement of research problem . . . . . . . . . . . . . . . . 27 
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . ._ . . . . . . . . . 30 
II. IDENTIFICATION OF IMMUNOGENIC, SURF ACE-EXPOSED 
OUTER MEMBRANE PROTEINS OF --
Pasteurella haemolytica SEROTYPE 1. . . . . . -. . . . . . . . . . . . . . . . 50 
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 
Introduction ... _ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 
Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 
Results ......................................... 58 
Discussion . . . . . . · . . . . . . . . . . -. . . . . . . . . . . . . . . . . . . . . . 60 
Acknowledgments ..... _ ............................ 64 
References . . . . . . . . . . . . . . . . . . . . . . . 65 
Figures ... _ ............... _ .......... _ ............ 71 
III. GENETIC AND IMMUNOLOGIC ANALYSES OF A 38 kDa SURFACE-
EXPOSED PROTEIN OF Pasteurella haemolytica Sl . . . . . . . . . . . . . 81 
Abstract . . . . _. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 
Introduction. . . . _. _. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83 
Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84 
Results . . . . . . . . .' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ·. . 88 
Discussion . . . . . . . . . . . . . ; . . . . . . .·- . . . . . . . . . . . . . . . . . 92 
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95 
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95 
Figures ........................................ 100 
iv 
IV. GENETIC AND IMMUNOLOGIC ANALYSIS OF PlpE, A LIPOPROTEIN 
IMPORTANT IN COMPLEMENT-MEDIATED 
KILLING OF P. haemolytica Sl. . . . . . . . . . . . . . . . . . . ..... 112 
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .113 
Introduction ..................................... 114 
Materials and methods .............................. 116 
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .122 
Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .125 
Acknowledgments ................................. 130 
Figures ........................................ 131 
References ...................................... 147 
V 
LIST OF TABLES 
Table Page 
I. List of P. haemolytica surface-exposed proteins as determined 
by protease treatment and serum absorption analyses ............ 79 
Vl 
LIST OF FIGURES 
Figure 
1. Western immunoblots of P. haemolytica whole cell lysates, 
prepared from protease-treated cells, probed with serum from 
Page 
an OMP-vaccinated calf. . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 
2. Western immunoblots of P. haemolytica whole cell lysates, 
prepared from protease-treated cells, probed with serum from 
a live P. haemolytica-vaccinated calf. . . . . . . . . . . . . . . . . . . . .73 
3. Western immunoblots of P. haemolytica whole cell lysates, 
prepared from protease-treated cells, probed with serum from 
a calf naturally exposed to P. haemolytica infection. . . . . . . . .75 
4. Western immunoblots of P. haemolytica whole cell lysates, probed 
with unabsorbed sera and sera absorbed 
with intact P. haemolytica . ........................... 77 
5. Western immunoblots of P. haemolytica outer-membrane 
and inner-membrane fractions and E. coli whole cell lysates probed 
with anti-Lpp38 Mab, 6A6E5 y . ........................ 100 
6. Nucleotide sequence of the gene encoding Lpp38 ............. 102 
7. Alignment of the deduced amino acid sequences of P. haemolytica 
Lpp38 and the E.coli proteins PotD and PotF. . . . . . . . . . . . 104 
8. Autoradiogram of SDS-polyacrylamide gel with 3H-palmitic 
acid-labeled total cellular lipoproteins .............. . . .. 106 
9. Western immunoblot of P. haemolytica cell envelope fractions 
and E. coli whole cell lysates probed with bovine sera. . . . . . . . .108 
10. Western immunoblots of P. haemolytica whole cell lysates 
prepared after treatment of intact cells with various proteases. . . . . 110 
11. Western immunoblots demonstrating surface exposure of 
PlpE in P. haemolytica and in recombinant E. coli . ............ 131 
vii 
12. The nucleotide sequence of plpE and the deduced 
amino acid sequence of PlpE. . . . . . . . . . . . . . . . . . . . . . . . . 133 
13. Hydrophilicity plot of the deduced amino acid sequence of PlpE. . . 135 
14. Alignment of the deduced amino acid sequences of 
PlpE and OmlA proteins from A. pleuropneumoniae 
serotypes 1 (OmlAl) and 5 (OmlA5) ........... . 
15. Western immunoblot demonstrating the effect of mutagenesis 
. .. 137 
of the GTG codon on production of PlpE. . . . . . . . . . . . . . . 139 
16. Autoradiograph of SDS-polyacrylamide gel of 3H-palmitate 
-labeled total cellular lipoproteins. . . . . . . . . . . . . . . . ... 141 
17. Western immunoblots of whole cell lysates of different 
P. haemolytica serotypes and an untypeable strain, probed 
with anti-45 kDa antibodies .......................... 143 
18. Complement-mediated killing activity of 







Introduction and review of relevant literature 
Louis Pasteur is often referred to as the father of medical microbiology. He 
discovered that fowl cholera was caused by bacteria, thereby providing the 
pioneering evidence that bacteria could cause disease in animals. In his 
honor the bacterial causative agent of fowl cholera was named Pasteurella 
multocida. Later similar, Gram-negative, . facultatively anaerobic, and 
fermentative bacteria were ~ncluded in the family Pasteurellaceae Pohl 
(Mutters et al., 1989). This family consi.sts of genera Actinobacillus, 
Haemophilus, and Pasteurella. Organisms in the genus Pasteurella can cause 
haemorrhagic septicemia, bronchopneumonia, meningitis, mastitis, abortion, 
and localized infection in cattle (Frank, 1989). 
In the United States, pneumonic pasteurellosis of cattle is one of the most 
important diseases associated with Pasteurella (Confer et al., 1990). Annual 
losses to the beef industry attributed to this disease are about one billion 
dollars (Dee, 1997). The disease is also called shipping fever and is 
characterized by acute fibrinous bronchopneumonia and pleuritis (Confer et 
al., 1988). Pneumonic pasteurellosis is precipitated by stress inducing 
conditions such as shipping, overcrowding; weaning, viral infections, and 
inclement weather. Pneumonic pasteurellosis is frequently the immediate 
cause of death in animals suffering from bovine respiratory disease (BRD) 
(Frank, 1989). BRD is a bigger entity than pneumonic pasteurellosis and 
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consists of lower respiratory tract infections of dairy and beef cattle caused by 
bacteria, viruses, and mycoplasma. Shipping fever is a term used to describe 
the fibrinous pleuropneumonia caused by Pasteurella in beef cattle. 
Pasteurella haemolytica serotype 1 (Sl) is the organism most commonly 
associated with shipping fever i.e., pneumonic pasteurellosis of beef cattle 
(Frank, 1989) (Confer et al., 1988) (Wilkie and Shewen, 1988). The disease has 
been reproduced experimentally in calves by transthoracic and intratracheal 
administration of P. haemolytica Sl alone (Ames et al., 1985) (Panciera and 
Corstvet, 1984). P. haemolytica have been typed into 17 serotypes based 
mainly on the antigenic nature of the capsular polysaccharides synthesized by 
these organisms (Biberstein, 1978) (Fodor et al., 1988) (Younan and Fodor, 
1995). Thirteen of the 17 serotypes ferment arabinose and are grouped under 
biotype A, whereas 4 ferment trehalose and are grouped under biotype T 
(Biberstein, 1978) (Younan and Fodor, 1995). More recently it has been 
demonstrated that biotypes A and T are notably different in their 165 r RN A 
gene sequences and belong to different phylogenetic clusters under the family 
Pasteurellaceae (Dewhirst et al., 1992). It has been proposed that the T strains 
be given a species name, P. trehalosi (Sneath and Stevens, 1990). 
Pathogenesis 
Despite numerous years of research, the pathogenesis of P. haemolytica 
pneumonia is not well characterized. Numerous reviews have put the 
available knowledge about P. haemolytica infection in perspective (Frank, 
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1989) (Whiteley et al., 1992) (Confer et al., 1995), Healthy calves, even those 
that have not encountered P. haemolytica, have host defense mechanisms 
that are capable of clearing a P. haemolytica infection (Frank, 1989). In 
contrast, lungs of calves that are immunocompromised due to viral 
infections, such as bovine herpesvirus-l(BHV-1) or parainfluenza-3 (PI-3) 
virus, are readily colonized by P. haemolytica (Frank et al., 1986) (Frank et al., 
1987). 
Viral infections play an important role in development of pneumonic 
pasteurellosis. BHV-1, PI-3 or bovine respiratory syncitial virus (BRSV) 
damage the mucosa of the respiratory tract and reduce pulmonary clearance 
(Confer et al., 1988); BHV-1 also modulates leukocyte function (Filion et al., 
1983). Although bovine viral diarrhea virus (BVD) does not directly affect 
pulmonary defense mechanisms, it causes generalized immunosuppression 
and enhances experimental pneumonic pasteurellosis (Lopez et al., 1982) 
(Potgieter et al., 1984). Other stress inducing factors such as inclement 
weather, overcrowding, and shipping also produce similar results, 
underscoring the role of stress in development of pneumonic pasteurellosis 
(Whiteley et al., 1992) (Jones, 1987). Stress in general causes 
immunomodulation which promotes colonization by P. haemolytica (Filion 
et al., 1984). It has been postulated that under stress the upper respiratory tract 
of cattle favors multiplication of P. haemolytica Sl over P. haemolytica S2 
(Confer et al., 1988). Only P. haemolytica Sl seem to have the capacity to 
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colonize the lung after inhalation, although the mechanism. by which they do 
so is not clear (Gonzalez and Maheswaran, 1993}. 
It is generally believed that P. haemolytica Sl are present in low numbers 
in the upper respiratory tract ·(URI) of calves, and under stressful conditions, 
they proliferate and are aerosolized into the lung (Frank, 1989) (Grey and 
Thom.son, 1971). P. haemolytica strains have also been isolated from. grass, 
drinking water, and, straw bedding used for sheep, where cold conditions 
seemed to favor their extended viability (Burriel, 1997). Thus fom.ites could 
play an im.p.ortant role in spread of P. haemolytica infection among animals 
in close contact. It is not clear, however, whether the strain that is present in 
the URI of an individual is also the strain that colonizes the lung or if cattle 
acquire a new strain during an outbreak of pneum.onic pasteurellosis. 
Limited information is available on the different strains within serotypes of 
P. haemolytica. Ribotyping, restriction endonuclease analysis, minim. um. 
inhibitory concentrations (MIC), and plasm.id content have . been used to 
com.pare isolates recovered from. feedlot cattle during a pneU:m.onic 
pasteurellosis outbreak (Murphy et al., 1993). That study identified 6 different 
strains including 2 · different ones from. a single animal. · Outer m.em.brane 
protein (OMP), lipopolysaccharide (LPS), and enzyme profiles analyses have. 
also been· used for com.paring isolates (Davies et al.; 1996) (Purdy et aL, 1997). 
Such studies should be helpful in understanding the epidemiology of · P . . 
haemolytica infection and m.ay provide useful insights into pathogenesis of 
the disease. 
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Bacterial factors associated with virulence 
Colonization of the URT mucous membrane seems to be the first and 
indispensable step towards the establishment of P. haemolytica infection. It is 
not clear whether P. haemolytica adhere to the URT mucosa or whether they 
remain in the mucus layer without adhering (Confer et al., 1995). Adherence 
could potentially take place through pili. Although pili have been 
demonstrated in P. haemolytica by one group of researchers, these results 
have not been verified by independent groups (Morck et al., 1987) (Potter et 
al., 1988) (Gonzalez and Maheswaran, 1993) (Confer et al., 1995). Hence, the 
expression of pili by P. haemolytica is debated. Consequently, their role, if 
any, in adherence of P. haemolytica remains undetermined. Outer 
membrane proteins (OMPs) and capsular polysaccharide preparations of P. 
haemolytica have been shown to adhere to bovine tracheal mucus (Botcher et 
al., 1993). 
In addition, a neuraminidase produced by P. haemolytica can cleave 
bovine mucin and could be a factor in promoting adherence of the organism 
to mucous membranes (Botcher et al., 1993) (Confer et al., 1995). The removal 
of sialic acid residue from salivary glycoproteins reduces their capability to 
function as a protective covering on the mucous membranes (Gottschalk, 
1960). Thus by cleaving the sialic acid residue from salivary glycoproteins, 
neuraminidase could serve as an important virulence factor for P. 
haemolytica, aiding in colonizing nasal mucous membranes (Straus et al., 
1993). However, this study could not determine if strains of A haemolytica 
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which lack the ability to produce neuraminidase were less virulent when 
compared to neuraminidase producing strains. Recently, antibodies against a 
sialoglycoprotease of P. haemolytica have been reported in sera of calves that 
were administered a commercial vaccin~ (Chiang et al., 1994). It was 
demonstrated that on challenge with live P. haemolytica, calves producing 
these anti-sialoglycoprotease antibodies had fewer pulmonary lesions, when 
lungs were examined post mortem (Chiang et al., 1994). However, a direct 
role for these specific antibodies, in protection against P. haemolytica 
infection was not established. 
Recently, a gene encoding serotype specific antigen (Ssa) was discovered in 
·. P. haemolytica Sl, .c:1nd its homologues in serotypes 2, 5, 6, 7, 9, and 12 were 
also demonstrated (Lo et al., 1991) (Gonzalez-Rayos et al., 1986)(Gonzalez et 
al., 1991). The gene encoding Ssal, when transformed int~ E coli, was able to 
confer a serotype 1 phenotype to the tecipier{t due to expression of Ssal 
protein (Gonzalez et al., 1991). This protein has been suggested to be another 
potential adherence. factor for P. haemolytica Sl (Gonzalez et al., 1991). 
However, evidence to support this suggestion is lacking. 
A capsular polysaccharide (CPS) produced by P. haemolytica was identified 
. by Corstvet et al., 1982. CPS is serotype specific and its structure was studied 
using chemical analysis and NMR spectroscopy (Adlam et al., 1984)'. CPS 
causes diminished phagocytosis and killing by bovine neutrophils and 
macrophages (Czuprynski et al., 1991a) (Czuprynski et al., 1987). Also 
encapsulated P. haemolytica were more resistant to serum agglutination and 
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complement-mediated killing as compared to decapsulated organisms (Chae 
et al., 1990). 
Leukotoxin (Lkt) is an important virulence factor of P. haemolytica that 
seems to help not only in overpowering the host immune response, but also 
in orchestrating the inflammatory response associated with the disease. Lkt is 
a secreted, pore-forming cytolysin, which is specific for bovine leukocytes and 
platelets (Clinkenbeard et al., 1989) (Clinkenbeard and Upton, 1991) (Shewen 
and Wilkie, 1982), Lkt also induces apoptosis in bovine leukocytes (Stevens 
and Czuprynski, 1996), down-regulates major histocompatibility complex 
class II (MHC-11), and induces histamine release by pulmonary mast cells 
(Hughes et al., 1994) (Adusu et al., 1994). Lkt is secreted in an aggregated form 
and this form is not as potent at lysing leukocytes as the disaggregated form. 
Bovine serum albumin was shown to be a potent stimulator of Lkt activity 
(Waurzyniak et al., 1994). It has been proposed that exudation of BSA-rich 
serum into lung alveoli during pneumonic pasteurellosis could cause the 
disaggregation of Lkt, thus enhancing its lytic activity on bovine leukocytes 
(Confer et al., 1995). On the other hand, when present in low concentration 
Lkt is a potent stimulator of bovine neutrophils in vitro (Czuprynski et al., 
1991b ). Activation of leukocytes could cause release of oxygen-free radicals in 
the surrounding tissue thereby increasing tissue necrosis (Confer et al., 1995). 
Thus it is not clear whether Lkt is more harmful in low doses by increasing 
neutrophil-mediated injury in the lung parenchyma or in high dose by 
causing neutrophil lysis. It is certain, however, that Lkt plays a major role in 
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the inflammatory process that leads to fibrinous pleuropneumonia as a result 
. of P. haemolytica infection. 
Lipopolysaccharide (LPS) of P. haemolytica is similar to that of other 
. . 
Gram-negative bacteria and contains biologically active lipid A (Rim.say et aL, 
1981) (Confer et al., 1990). LPS induces adherence of neutrophils to bovine 
pulmonary artery· endothelial cells and causes activation of arterial 
· endothelial cells (release of arachidonic acid), processes that are important in 
the inflammatory pathways, like leukocyte extravasation, . associated with 
pneumonic pasteurellosis {Paulsen et al., 1989). LPS also induces the release 
of proinflammatory cytokines in bovine alveolar macrophages (Yoo et al., 
1995). An LPS~associated protein (LAP) has also been demonstrated to induce 
pulmonary inflammation when deposited in the lung of calves (Brogden. et 
al., 1995a). Thus LPS of P. haemolytica is an important virulence factor 
involved in the development of an acute inflammatory response. 
P. haemolytica express novel periplasmic protein of 35 kDa and outer 
membrane proteins of 71, 73, and 100 kDa when grown in iron-restricted . 
culture conditions or in vivo (Murray et al., 1992) (Deneer and Potter, 1989) 
(Morck et al., 1991) (Ogunnariwo and 'Schryvers,. 1990). These proteins might 
be considered as virulenc~ factors, because they are expressed in vivo and may 
be important in the acqqisition of iron in an environment where no free ir.on 
is available (Yu et al.~ 1992) (Morck et al., 1991). 
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Immunological importance of P. haemolytica molecules 
Leukotoxin 
As described above Lkt is a pore-forming cytolysin, belonging.to the family 
of RTX toxins, and it specifically lyses ruminant leukocytes and platelets · 
(Confer et al., 1995). If Lkt is an important virulence factor, it is logical to 
assume that antibodies against this molecule would aid in development of 
· resistance to pneumonic pasteurellosis by neutralizing the harmful effects of 
leukotoxin on its target cells. Indeed serum--neutralizing antibodies against 
Lkt directly correlated with resistct.nce to experimental P. haemolytica 
challenge (Gentry et . al., 1985). Addition of recombinant leukotoxin 
containing supernatant . to a commercial vaccine, enhanced the protective 
capacity of the vaccine; however, vaccination of cattle with recombinant Lkt 
alone failed to protect cattle against· experimental challenge (Conlon et al., 
1991) (Purdy. et al., 1993). These results corroborate earlier findings that· 
antibody responses against both Lkt and other surface antigens are required 
for development of immunity to P. haemolytica infection (Shewen and 
Wilkie, 1988). The use of Lkt in commercial vaccines is discussed in a later 
section on P. haemolytica vaccine studies. 
Capsular polysaccharide 
The capsular polysaccharide . (CPS) from. P. haemolytica Sl has been 
purified and characterized, and its · immunological properties have been . 
studied (Adlam et al., 1984). Antiserum raised against the partially purified 
form of P. haemolytica Sl capsule was found to be specific against the 
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homologous serotype; and in an immunodiffusion test, it did not precipitate 
antigens from other serotypes (Adlam et al., 1984). Indeed, antiserum raised 
against the capsular antigen is used to differentiate P. haemolytica into 16 
serotypes (Frank, 1989). Immunization of calves with P. haemolytica capsular 
, antigen or with live or killed P. haemolytica induces an immune response to 
capsular polysaccharide; however, this immune response does not correlate 
with development of resistance to pneumonic pasteurellosis (Confer et al., 
1989). Vaccination of calves with CPS. failed to· protect cattle against 
experimental challenge (Conlon and· Shewen, 1991). In a · recent study, 
however, it was demonstrated that the protective ability of CPS as an 
. : . . 
. . 
immunogen could be significantly increased by using muramyl dipeptide 
analogs as adjuvants (Brogden et al., 1995b). In another study, preparturient 
vaccination of dams was used as a technique to enhance passive immunity of 
dairy calves to CPS of P. haemolytica Sl (Hodgins and Shewen, 1996). 
However, this study did not analyze the correlation between these passively 
acquired antibodies and resistance to pneumonic pasteurellosis. Confer et.· al. · 
(Confer et al., 1989) studied the role of carbohydrate protein subunit (CPS), 
which contains capsular carbohydrate along with low concentrations of LPS 
and outer membrane proteins, as an immunogen. They reported that serum 
.· antibodies that are important in resistance to pneumonic pasteurellosis are 
mainly directed against the periodate-resistant (protein) epitopes of CPS; 
however, some carbohydrate epitopes may also be important. Hence it 
appears that although CPS may be an important virulence factor of P . . 
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haemolytica (discussed previously), its role as an immunogen in 
·· development of resistance to P. haemolytica infection may be rather limited 
and needs additional study. 
Lipopolysaccharide 
Although LPS might-be an important virulence fa,ctor of P. haemolytica, it 
does not seem to be an important target of the host immune response. High 
serum antibodies to LPS 0-antigens did· not correlate with resistance to 
experimental bovine pneumonic pasteurellosis (Confer ... et al., 1986). 
Vaccination with LPS failed· to protect calves against · experimental 
transthoracic challenge With P. haemolytica (Purdy et aL, 1993). An LPS 
' ' ' 
subunit vaccine Was also ineffective in. development of resistance · to 
pneumonic pasteurellosis in a experimental goat model (Purdy et al., 1993). 
Outer membrane proteins (OMPs) including IROMPs 
Antibodies against OMPs of Gram-negative bacteria can be important in 
development of resistance to infection, by promoting phagocytosis and by 
impairing the function of these OMPs. Similarly, an immune response 
against P. haemolyti_ca OMPs could be important in the development of 
resistance to pneumonic pasteurellosis (Squire et al., 1984). Indeed 
vaccination of cattle with OMP-enriched fractions of P. haemolytica Sl 
significantly reduced lung damage · upon experimental exposure with 
homologous serotype (Morton et al., 1995). Earlier research demonstrated 
that antibodies against the protein and not the carbohydrate component of the 
carbohydrate-protein subunit (CPS) correlated with development of resistance 
12 
to experimental P. haemolytica infection (Gentry et al., 1982) (Confer et al., 
1989). Further immunological. analysis of CPS indicated that antibody 
responses against antigens of 86, 66, 51, 49, 34, 31, and 16 kDa correlated with 
resistance to pneumonic pasteurellosis (Mosier et al., 1989a). It was also 
demonstrated that antibodies against surface antigens of P. haemolytica, 
including OMPs, are important in protective efficacy of a recombinant Lkt-
containing commercial vaccine, Presponse® (Conlon et al., 1991). OMPs can 
also serve as potentially important cross-protective antigens. Antisera from 
cattle vaccinated with P. haemolytica Sl showed significant antibody 
responses against various OMPs of eight untypeable strains of P. haemolytica 
(Simons et al., 1992). These data suggest that an immune response against P. 
haemolytica OMPs might be an important component of a protective 
immune response. 
OMPs are promising immunogens of P. haemolytica, and the nature of 
immune response against these antigens has been further scrutinized. 
Because antibodies directed against the surface antigens are considered to be 
important in aiding antibody-dependent host defense mechanisms, it is 
important to determine which OMPs exhibit surface-exposed epitopes. 1251-
labeling was employed to determine that 94, 84, 53.5, 49, 43, 41, 29.5 and 16 kDa 
OMPs have surface-exposed domains (Morton et al., 1996). This technique 
relies on reaction of 1251-iodine with surface-exposed tyrosine residues, 
consequently, a surface-exposed OMP that lacks an exposed tyrosine residue 
would go undetected (Richardson and Parker, 1985). Knights et al., 1990, 
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identified surface-exposed OMPs of P. haemolytica S2 by studying their 
susceptibility to extracellular proteases and their ability to absorb out 
antibodies from hyperimmune rabbit serum. However, the results of this 
study cannot be directly extrapolated to P. haemolytica Sl OMPs, because the 
OMP profiles of these two serotypes • have been shown to quite different 
(McCluskey et al., 1994). McCluskey et al., 1994, also compared the OMP 
profiles of 18 isolates within serotype 1 and found four different patterns of 
OMP-profiles. Hence, a study using more comprehensive . techniques than 
1251-iodine labeling is needed to establish the· repertoire of surface-exposed 
. . 
OMPs of P. haemolytica $1. This need has been addressed in the research 
presented in chapter.1 of this dissertation. 
Study of surface~exposed OMPs could benefit from the production of 
surface-reactive monoclonal antibodies (MAbs) against these proteins. MAbs 
. . 
were raised against OMl>s of 29 kDa and 66 kDa, (Austin et al., 1992); however, 
these antibodies did not recognize surface-exposed epitopes. Doig et al. 
produced MAbs against OMPs .of Helicobacter pylori and screened them on 
the basis of their reactivity to whole cells in ELISA, immunoflourescence, and 
immunoelectron microscopy (Doig and Trust, 1994). · This technique resulted 
in isolation of 17 MAbs against surface-exposed epitopes and could be applied 
to isolate surfac~.:.readiveJ\1Abs against P. haemolytica.· 
Studies have also been directed towards understanding the roles of 
individual P. haemolytica OMPs in the pathogenesis of P. haemolytica 
infections and in development of resistance to pneumonic pasteurellosis. · 
14 
Using recombinant DNA technology a segment of P. haemolytica DNA was 
cloned that encoded proteins of 28, 30, and 32 kDa (Craven et al., 1991). Rabbit 
antibodies raised against P. haemolytica 30 kDa protein caused agglutination 
of whole P. haemolytica, suggesting that this protein exhibits surface-exposed 
epitopes (Craven et al., 1991). Analysis of the DNA sequence revealed that the 
three proteins of 28-30 kDa are transcribed off a single promoter (Murphy and 
Whitworth, 1993). · The recombinant forms of these three proteins were 
utilized to prove that they are lipid modified and that they are 
immunologically distinct (Dabo et al., 1994). Bovine antibody response 
against one of these 28-30 kDa lipoproteins correlated with resistance to 
pneumonic pasteurellosis (Dabo et al., 1994). ·. Recently two OMPs of 32 and 35 
kDa (PomA and PomB, respectively) have been characterized (Mahasreshti et 
al., 1996). PomA was determined to be the P. haemolytica homologue of an E. 
coli protein OmpA and was demonstrated to exhibit surface-exposed domains 
(Mahasreshti et al., 1996). Also, cattle vaccinated with live P. haemolytica 
showed a significant increase in antibodies to PomA and PomB (Mahasreshti 
et al., 1996). Further investigation into the role of PomA in immunity to P. 
haemolytica infection is currently under progress in Dr. Murphy's laboratory. 
A secreted 60 kDa protein of P. haemolytica has also been recently cloned; 
however, this study did not characterize the nature of this antigen (Lo and 
Mellors, 1996). Antibody responses against the 60 kDa protein correlated with 
resistance to pneumonic pasteurellosis (Weldon et al., 1994). Similarly a 100 
kDa, serotype-specific OMP of P. haemolytica has been cloned and sequenced 
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(Lo et al., 1991). Others have determined that the DNA encoding this protein 
is also present in other serotypes; however, its expression, which is controlled 
at the transcriptional level, is only allowed in serotype 1 (Gonzalez et al., 1995) 
(Gonzalez et al., 1991). The role of this protein in immunity and/ or 
pathogenesis has been speculated (discussed previously); although significant 
data has not been collected to support or prove it (Gonzalez et al., 1995) (Lo et 
al., 1991). 
Although the above mentioned studies provide circumstantial evidence 
supporting the role of antibodies against these specific proteins in 
development of a protective immune response, a more detailed investigation 
into the role of antibodies in host defense mechanisms is lacking. Such 
investigations are critical if these proteins are to be considered in the 
development of an efficient subunit vaccine, espedally in light of the fact that 
antibodies against certain OMPs of other Gram-negative pathogens have been 
shown to block host immune mechanisms (Joiner et al., 1985). 
Several other researchers have studied OMPs for their roles in 
mechanisms other than immunity. A 35 kDa P. multocida protein has been 
shown to facilitate the binding of the organism to respiratory mucus and to 
epithelial cell wall preparation (Lubke et al., 1994). A similar 44 kDa P. 
haemolytica antigen was also identified in this study. N-terminal regions of 
these proteins were found to be similar to E. coli OmpC and OmpF porins 
(Lubke et al., 1994). However, no trimers (characteristic of porins) of the 44 
kDa P. haemolytica protein were observed. Mpal, a P. haemolytica protein 
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that is located in the cytoplasmic membrane and is homologous to bacterial 
PurK proteins has been cloned and sequenced (Chang et al., 1993). PurK is 
involved in de nova purine biosynthesis, but the function of Mpal has not 
been studied. · A gene encoding a periplasmic binding protein of P. 
haemolytica, LapT was cloned and overexpressed in E. coli (Caskey et al., 
1996). LapT was purified from these recombinant E. coli and binding assays 
were employed to determine that LapT is a.n arginine-binding protein (Caskey 
et al., 1996). This study also reported that arginine is not important for 
growth of P. haemolytica, hence a LapT mutant may have little potential as 
an attenuated live P. haemolytica vaccine candidate. However, previous 
studies by the same laboratory suggest that the arginine transport locus has a 
negative effect on leukotoxin expression (Highlander et al., 1993). Further 
studies will be required to understand the role of the above mentioned 
proteins in the physiology and virulence of P. haemolytica. 
Mutational analysis of P. haemolytica antigens 
As described above, numerous P. haemolytica antigens have been 
associated with pathogenesis of the pneumonic pasteurellosis and in 
development of immunity to P. haemolytica infection. Null mutations of 
genes responsible for the production of these molecules would be extremely 
helpful in delineating their role in P. haemolytica infection and immunity. 
A chemical mutagenesis approach, using nitrosoguanidine, was employed to 
abolish the production of Lkt in P. haemolytica (Chidambaram et al., 1995) 
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· (Petras et al., 1995). This approach yielded two mutants that lacked Lkt 
production. One of these mutant strains was shown to have reduced 
virulence in goat and cattle challenge experiments (Petras et al., 1995). This 
mutant could serve as an important tool in unders~anding the role of Lkt in 
. . 
pathogenesis of P. hacmolytica infection. However, chemical mutagenesis is 
. . . 
a random process so there is always a possibility that more than one gene has 
been affected thereby making it difficult to interpret the effects of the 
mutation (Chidambaram et al., 1995). 
Specific gene.targeting is a more desirable approach to mutagenesis and is 
possible through homologous recombination. Mutants developed through 
this approach are genetically defined and hence more useful for studying the 
functions of particular g~nes. Homologous recombination has recently been 
used to develop a mutant P. haemolytica Sl that is deficient in production of 
the three contiguous lipoproteins (Lpp) around 30 kDa (mentioned above) 
and also to develop a mutant lacking in production of Lkt (Murphy and 
Whitworth, 1994) (Murphy et al., 1995). The lpp30 mutant had reduced 
growth rate and increased· susceptibility to bovine serum antibodies in 
complement-mediated. killing. (Murphy et al., sub1:1-itted). This mutation · 
causes the production of IROMPs under iron-sufficient conditions. The Lkt 
mutant failed to show ~,:.hemolytic activity on sheep anq rabbit blood agar 
plates confirming the role of Lkt as a hemolysin (Murphy et al., 1995). This 
Lkt mutant has also served as a useful control in studying the role of Ca++ 
. influx in neutrophil activation and lysis mediated through Lkt (personal 
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communication with Dr. K.D. Clinkenbeard and Dr. C.R. Clark). This mutant 
is also likely to be deficient in production of other proteins encoded by the 
operon Lkt CABD. As a result this mutant could also serve as a useful tool to 
determine if P. haemolytica employs the Lkt secretory mechanism to 
transport proteins other than Lkt. Very recently, Tatum et al., 1998, have 
reported the construction of another. Lkt mutant by allelic replacement. This 
mutant has a marked reduction in virulence, as determined by decreased 
lung lesion scores in an· experimental calf model of pneumonic 
pasteurellosis. · Histologically, lung of Ll<t mutant-infected calves showed 
reduced necrosis and lack of leukocyte degeneration. This study has fortified 
the view that Lkt plays an important role in the pathogenesis of P. 
haemolytica bronchopneumonia 
Attenuated mutant strains can potentially be used as live vaccines. With 
this objective in mind, two auxotrophic mutants have been produced. Both 
these mutants were produced by allelic exchange of aroA gene (Homchampa 
et al., 1994) (Tatum et al., 1994). The product of this gene is involved in 
biosynthesis of aromatir amino acids, and bacteria with defective aromatic 
amino acid synthesis. pathways have been shown to be attenuated and 
avirulent (reviewed in Tatum et al., 1994). The aroA mutant . developed by 
Homchampa et al., . i994, was demonstrated to be highly attenuated in a 
mouse septicemia model of P. haemolytica infection. The efficacy of these 
mutants as live vaccine candidates in cattle remains to be determined. 
Similarly, galE mutants of Niesseria gonnorrhoeae and Salmonella 
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typhimurium have been shown to have decreased virulence (Hone et al., 
1987) (Robertson et aL, 1993). GalE is involved in production of LPS and to 
some extent in CPS. The galE locus of P. haemolytica has been cloned and 
characterized (Potter and Lo, 1996). A GalE- strain of P. haemolytica could be 
potentially useful as an attenuated live vaccine candidate. However, no such 
mutant strains have so far been reported. 
Vaccines 
Vaccination of cattle with live P. haemolytica has been shown to confer 
the most consistent resistance to experimental challenge with P. haemolytica 
(Purdy et al., 1993) (Confer et al., 1985) (Blanchard-Channell et al., 1987). 
However, field trials using live vaccines have given inconsistent results 
(Purdy et al., 1986) (Smith et al., 1985). Also, intradermal vaccination with 
live P. haemolytica is associated with development of localized swelling, 
while vaccination through an intramuscular route may lead to lameness and 
fever (Confer et al., 1988). Zeman et al., 1993, reported systemic P. haemolytica 
infection as result of vaccination with an avirulent P. haemolytica strain. On 
the other hand, vaccination of cattle with P. haemolytica bacterins has either 
failed to protect cattle against the disease or caused an enhancement of the 
disease (Confer et al., 1985) (Friend et al., 1977) (Martin, 1983) (Wilkie and 
Markham, 1979). However, a recent study demonstrated that vaccination 
with a tissue culture derived formalin fixed P. haemolytica vaccine caused 
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inhibition of nasal and tonsillar cplonization by homologous serotype (Frank 
et al., 1994). 
Other attempts at developing vaccines have focused on the use of bacterial 
components. A vaccine containing . recombinant Lkt along with P. 
haemolytica culture supernatant, was studied for its ability to induce a 
protective immune response (Conlon et al., 1991).· In that study, it was 
. . 
observed that vaccination of calves· with culture supernatant and 
recombinant Lkt provided significant ·protection; however, recombinant Lkt 
alone failed to protect calves against experimental P. haemolytica challenge 
(Conlon et al., 1991). Ttansthoracic vaccination with agar beadsimpregnated 
with lipopolysaccharide or Lkt failed to induce protection against 
.transthoracic challenge with live P. haemolytica, while transthoracic 
vaccination with agar beads impregnated with capsule antigen could only 
induce partial protection (Purdy et al., 1993). Harland et al., 1992, studied the 
effect of a subunit or modified live bovine herpes virus-1 (BHV-1) vaccine on 
the .. efficacy of a vaccine containing OMPs of P. haemolytica and genetically 
attenuated Lkt. They observed that subu,nit vaccine comprised of BHv.:.1 
glycoproteins, when administered along with P. haefnolytica vaccine, 
conferred a significant protection, while vaccination ~ith modified live BHV-
1 and parainfluenza-3 interfered with protection conferred by the P. 
haemolytica vaccine. Another subunit vaccine containing genetically altered 
Lkt and bacterial extracts of both P. haemolytica and Haemophilus somnus 
significantly reduced bovine respiratory disease morbidity (Donkersgoed et al., 
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1993). Vaccination with two commercial vaccines, Septimune®PH-K (Fort 
Dodge laboratories, Fort Dodge, IA) or One Shot™ (SmithKline Beecham 
Animal Health, Lincoln, NB) significantly increased antibodies against 
surface antigens and Lkt and also induced significant resistance to 
experimental P. haemolytica infection (Confer and Panciera, 1994). 
Recently, the protective abilities of different experimental subunit 
vaccines, which contained different combinations of P. haemolytica 
immunogens, were studied (Sreevatsan et al.,· 1996). This · study concluded 
that serum antibodies against. Lkt, IROMPs, and capsular polysaccharide 
correlated with low lung lesions scores, upon experimental P. haemolytica 
challenge.· The effect of route of vaccination on its protective ability was also 
studied, and it was demonstrated that aerosol exposure with a virulent· P. 
haemolytica strain provided better protection against homologous challenge 
. than subcutaneous vaccination with the same strain (Newman et al., 1982). 
However, subcutaneous vaccination with an H. somnus and P. haemolytica 
vaccine containing attenuated Lkt was able to provide significant protection 
to feedlot cattle (Donkersgoed et al., 1993). 
A meta-analysis has been conducted to compare the efficacy of different 
experimental and commercial vaccines used in the past 12 years (Srinand et 
al., 1995). This statistical analysis revealed that cattle vaccinated with live P. 
haemolytica had the lowest lung-lesion scores, suggesting that live P. 
haemolytica provide the most significant protection against pneumonic 
pasteurellosis. However as mentioned above, vaccination with live P. 
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haemolytica can lead to complications. Culture supernatant and KSCN 
(potassium. thiocynate) extract vaccines, which contain numerous OMPs, also 
conferred significantly better protection than bacterins (Srinand et al., 1995) . 
. These vaccines were not as· efficacious as live vaccines. 
These vaccine trials su,ggest that im.m.unity to P. haemolytica is likely to be 
m.ultifactorial and associated with numerous cell-surface and extracellular 
molecules including OMPs. To determine the. exact role played by these 
molecules in im.m.unity to pneumonic pasteurellosis, it is important that. 
each factor be examined individ.tially. ·. One approach to this problem. would 
include isolating the genes which encode these P. haemolytica im.m.unogenic 
factors, characterizing the indi,vidual molecules, their·genes, and the im.m.une 
response against these molecules, by using recombinant clones and 
recombinant gene products in in vitro and in vivo analyses. As discussed 
above, m.utagenesis could be· another useful tool; however, mutations in . 
certain genes can prove to be lethal, thus limiting . the application of this 
powerful technique. 
Host Deferise Mechanisms 
Because P. haemolytica remains extracellular . in bovine pneum.onic 
pasteurellosis, hum.oral im.m.unity is. probably most important in protection 
against infection. Purdy et al. (Purdy et al., 1991) reported a decrease in the 
serum. com.plem.ent levels of calves exposed to stress by travel and · 
overcrowding. Also, calves showing morbidity due to P. haemolytica 
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infections, had lower levels of serum complement than healthy calves (Purdy 
et al., 1991). P. haemolytica cells are susceptible to complement-mediated 
killing, by bovine serum (MacDonald et al., 1983) (Chae et al., 1990). It has 
been demonstrated that antibodies are required to initiate the complement 
cascade (classical pathway), whereas direct activation of the complement in an 
antibody-independent fashion (alternate pathway) did not induce killing of P. 
haemolytica (MacDonald et al., 1983). These observations suggest a protective 
role for complement in pneumonic pasteurellosis. Which bacterial 
molecules elicit antibodies that mediate complement-,mediated killing is 
however unknown and needs to be . investigated. Possible targets of 
complement-fixing antibodies could be the surface-exposed domains of OMPs 
of P. haemolytica. 
IgG has been demonstrated to be the host serum antibody isotype most 
important ih protection against P. haemolytica infection (Mosier et al., 1989b). 
Although IgM levels in serum and bronchioalveolar lavage fluid are high in· 
the early phase of infection, IgG seems tb be more important subsequently 
(M<;:Bride et al., 1992). M:cBride et al., 1992, failed to detect any significant 
levels of IgA in the bronchioalveolar lavage fluid after experimental exposure 
to P. haemolytica. However, a surfactant-associated anionic peptide of low 
molecular weight has been demonstrated in ovine pulmonary secretions that 
is bactericidal to P. haemolytica (Brodgen et al., 1996). This and similar· 
proteins are expected to play an important role.in innate immunity against P. 
haemolytica especially in the absence of significant levels of IgA 
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Neutrophils are important in the pathogenesis of P. haemolytica-ind uced 
fibrinous pleuropneumonia. Neutrophils are extravasated into the lungs in 
large numbers when the lungs are colonized by P. haemolytica (McBride et al., 
1992), and their degeneration, which is partly due to Lkt-mediated lysis, 
results in the release of inflammatory mediators and lysosomal enzymes 
which cause tissue damage (Slocombe et al., 1985) (Vandenbroucke-Grauls et 
al., 1987). P. haemolytica culture· fluid has been demonstrated to induce 
chemotaxis, oxygen burst, and superoxide anion release from bovine 
neutrophils (Mdurvwa and Brunner, 1994). Lkt also causes an increased 
secretion of a proinflammatory eicosanoid, leucotriene B4 (LTB4), from 
bovine leukocytes (Clinkenbeard et al., 1994). A protective effect of 
neutrophil depletion against P. haemolytica infection has been suggested 
(Slocombe et al., 1985); however, Breider et al., 1988, demonstrated that P. 
haemolytica can also induce lung injury through neutrophil-independent 
mechanisms. In the latter study the intensity of lung injury was less in 
neutrophil-depleted than in normal calves. Neutrophils are also important 
in host defense against P. haemolytica; they have been demonstrated to kill 
high concentrations of the organism before Lkt causes their lysis (Czuprynski 
et al., 1987). In the presence of immune serum, neutrophils significantly 
reduced the endothelial cell damage caused by direct application of P. 
haemolytica to endothelial cells (Sharma et al., 1992). It appears that the role 
of neutrophils in pathogenesis of pneumonic pasteurellosis is rather 
complex. On the one hand they release cytotoxic and proinflammatory factors 
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that cause exacerbation of the disease, while on the other hand, they are 
important in killing P. haemolytica and to some extent protect against the 
direct cytotoxicity caused by the organism. 
Alveolar macrophages are a · component of the innate immune 
mechanism of the lungs. They are, therefore, expected to play a role in 
resistance to the colonization of the bovine lung by P. haemolytica. The 
bactericidal effects of alveolar macrophages is dependent on the concentration 
of P. haemolytica (Morales et al., 1994). Experimental intrabronchial 
administration of P. haemolytica in mice led to an increase in the number of 
macrophages in interalveolar septa and also in alveoli (Pace et al., 1994). 
However, Czuprynski et al., '1991a, found that the phagocytic activity of 
bovine macrophages is significantly reduced by the capsular polysaccharide of 
P. haemolytica. These authors argue that because of the inhibitory effects of 
factors such as capsular polysaccharide, Lkt, stress, and viral infection on 
phagocytosis, alveolar macrophages may only have a limited antibacterial 
activity against P. haemolytica during pneumonic pasteurellosis (Czuprynski . 
et al., 1991a) (Himmel et al., 1982) (Walker et al., 1984). 
Alveolar macrophages may, however, play a considerable role in the 
pathogenesis of pneµmonic pasteurellosis. Morphological studies show that 
exposure of alveolar macrophages to LPS causes changes that are consistent 
with activation (Whiteley et al., 1991). P. haemolytica endotoxin causes the 
release of proinflammatory cytokines, such as tumor necrosis factor (TNF) a. 
and interleukin-1~ (IL-1~) from bovine alveolar macrophages (Yoo et al., 
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1995) (Bienhoff et al., 1992). When stimulated by LPS, alveolar macrophages 
also release nitric oxide, a mediator that modulates hemodynamics in the 
immediate vicinity of its production (Yoo et al., 1996). The release of TNF a. 
and interleukin-1~ from the. macrophages subsequently enhances the 
endotoxin-mediated injury to endothelial cells (Sharma et al., 1992). The 
studies discussed above suggest that the role of alveolar macrophages in 
development of resistance to P . . haemolytica . infection may be limited;·· 
however, they are important players in the induction of an acute . 
inflammatory response that is associated with pneumonic pasteurellosis. 
Summary and statement of research problem 
The review of relevant literature suggests that P. haemolytica induced 
fibrinous pleuropneumonia in calves. is a complex disease process. The stage 
is set by one or more stress-inducing factors that have a detrimental effect on . 
the host immune system. This is followed by proliferation of P. haemolytica 
in the URT of these stressed calves and subsequently their aerosolization into 
the lungs. In the lungs, P. haemolytica proliferate rapidly and interact with 
the host immune components· to induce an acute and invasive fibrinous 
bronchopneumonia .. and pleuritis. It appears that an excessive and 
indiscriminate host immune response plays a. significant role in the 
exacerbation of the lung lesion associated with the disease. Nevertheless, it is 
possible to induce a protective immune response against pneumonic 
pasteurellosis as is best seen in the cases of vaccination with live P. 
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haemolytica. Live vaccines, however, have several undesirable side effects. 
Development of an attenuated P. haemolytica strain for use as a vaccine may 
help in alleviating complications of live vaccines; but there is always a chance 
of an avirulent strain reverting to its virulent form. A better approach would 
be to develop an efficient sub-unit vaccine that provides the protection of a 
live vaccine without the untoward side effects. 
In order to develop an efficacious sub-unit vaccine, it is important to 
characterize an effective host immune response. For this purpose, the 
immune response of cattle that have been found resistant to experimental P. · 
haemolytica infection should be comprehensively studied. Specific OMPs of 
P. haemolytica, especially those with surface-exposed domains, are expected to 
be crucial components of an efficacious subunH vaccine. To determine the 
potential of specific OMPs as vaccine candidates, OMPs should be studied 
individually and the roles of antibodies against these OMPs in host defense 
mechanisms should be clearly and unequivocally established. Molecular 
cloning and recombinant DNA technology are powerful tools that can be 
successfully used in achieving the above mentioned goals. 
One of the objectives of my research project was to identify the repertoire 
of surface-exposed OMPs of P, haemolytica Sl by analysis of susceptibility of 
OMPs, when present on intact P. haemolytica, to ~xtracellular proteases. 
Surface exposure was also determined by assaying for the ability of intact P . 
. haemolytica to adsorb out antibodies against these immunogenic and surface 
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exposed OMPs from immune sera of cattle that were resistant to experimental 
P. haemolytica infection. 
Two OMPs namely, Lpp38 and PlpE, that have surface-exposed domains 
were examined. The genes encoding these proteins were cloned and 
analyzed. The recombinant E coli clones that expressed these proteins were 
used to study the bovine immune response against these proteins. We 
determined that Lpp38, although very immunogenic, was only minimally 
surface exposed. On the other hand, PlpE, which is also the target of a 
significant immune response, had numerous surface-exposed regions. We 
decided to determine the role of antibodies against PlpE in complement-
mediated killing and found that absorbing out anti-PlpE antibodies from 
bovine immune serum caused a significant decrease in complement-
mediated killing of P. haemolytica. 
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Chapter II 
IDENTIFICATION OF IMMUNOGENIC, SURFACE-EXPOSED 




Pasteurella haemolytica serotype 1 (Sl) is the bacterium most frequently 
recovered from the lungs of cattle that have succumbed to shipping fever 
pneumonia. P. haemolytica outer membrane proteins (OMPs) are important 
immunogens in the development of resistance to pneumonic pasteurellosis. 
The purpose of this study was to identify the repertoire of immunogenic, 
surface-exposed P. haemolytica (Sl) OMPs, that could be important in the 
development of protective immunity. We determined surface-exposure of 
OMPs by (1) their susceptibility to protease treatment and (2) their ability to 
adsorb out antibodies from bovine immune sera. For a comprehensive 
identification of immunogenic, surface-exposed OMPs, we used bovine 
antisera from calves that were resistant to experimental P. haemolytica 
challenge after (1) natural exposure to P. haemolytica, (2) vaccination with 
live P. haemolytica, or (3) vaccination with P. haemolytica OMPs. We 
identified 18 immunogenic, surface-exposed P. haemolytica OMPs. Most were 
recognized by all three immune sera. However, some were recognized by one 
or two of the three antisera. Our analyses identified surface-exposed, 
immunogenic proteins that were not identified in previous studies. 
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Introduction 
Pasteurella haemolytica serotype 1 is the bacterium most commonly 
associated with shipping fever, a disease of beef cattle characterized by 
fibrinous pleuropneumonia (Frank, 1986; Frank, 1989; Whiteley et al., 1992). 
Conditions that lead to stress in cattle, such as shipping, viral infections, and 
inclement weather may cause immunosuppression and reduction of bacterial 
clearance, thus predisposing the lungs to colonization by P. haemolytica 
(Confer et al., 1988; Confer et al., 1990). Numerous P. haemolytica 
immunogens have been studied, and their roles in development of resistance 
to P. haemolytica infection have been evaluated (reviewed in (Confer, 1993)). 
Outer membrane proteins (OMPs) have been proposed to be important in 
the pathogenesis of pneumonic pasteurellosis and in development of a 
protective immune response against the disease (Confer et al., 1990; Confer, 
1993; Morton et al., 1995; Squire et al., 1984b; Sreevatsan et al., 1996). 
Vaccination with P. haemolytica outer membranes protected cattle against 
experimental challenge with the homologous serotype (Morton et al., 1995). 
Additionally, results of a recent meta-analysis (Srinand et al., 1995), in which 
twenty-seven vaccine efficacy studies were evaluated, revealed that vaccines 
delivering OMPs and other surface antigens, extracted from cells with 
different media, provided the best protection against P. haemolytica 
challenge. Protection afforded by those vaccines was comparable to that 
afforded by live vaccines. 
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In addition to providing protection against P. haemolytica strains of the 
homologous serotype, OMPs extracted from P. haemolytica serotype 1 also 
have potential for providing immunity against pneumonia caused by 
heterologous serotypes. Antibodies, stimulated by vaccination of cattle with 
P. haemolytica serotype 1 OMPs, recognized numerous OMPs from 
untypeable P. haemolytica strains, and the antibody response against several 
of those correlated with resistance to experimental P. haemolytica challenge 
(Simons et al., 1992). Similarly, when cattle are vaccinated with outer 
membranes from P. haemolytica serotypes 6 or 9, some protection is afforded 
against experimental challenge with a serotype 1 strain (Morton et al., 1995). 
Antibodies against surface-exposed P. haemolytica OMPs and other surface 
antigens are likely to enhance opsonization of the bacterium and contribute 
to (1) inhibition of . colonization (Frank et al., 1996), (2) phagocytosis and 
killing by neutrophils and macrophages (Breider et al., 1991; Chae et al., 1990; 
Czuprynski et al., 1987; Sharma et al., 1992), and (3) complement-mediated 
lysis (Chae et al., 1990; MacDonald et al., 1983; Penaredondo et al., 1988; 
Sutherland et al., 1989) . 
The identification of envelope proteins, OMPs, and surface-exposed OMPs 
that are produced. by various serotypes of P. haemolytica have been active 
areas of research (Davies et al., 1992; Donachie et al., 1984; Knights et al., 1990; 
McCluskey et al., 1994; Morton et al., 1996; Rossmanith et al., 1991; Squire et 
al., 1984a). Using 125J-labeling of whole cells, others have identified surface 
proteins from a P. haemolytica serotype 1 strain (Craven et al., 1991; Morton et 
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al., 1996). However, those studies did not examine the immunogenicity of 
the 125I-labeled OMPs. Similarly, several studies have examined· the host 
antibody response to OMPs from various P. haemolytica serotypes, but the 
presence of surface-exposed regions on those OMPs was not evaluated 
(McCluskey et al., 1994; Simons et al., 1992). Mosier etal. (1989) evaluated the 
bovine immune response to antigens present in a saline extract of whole P. 
haemolytica serotype 1. That study identified 13 saline-extracted antigens that 
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are recognized by immune bovine sera. Knights et. al (Knights et al., 1990) 
performed a comprehensive analysis of potentially immunogenic and 
surface-exposed OMPs produced by a serotype 2 strain. The proteins were 
identified by assaying for the ability of intact P. haemolytica to absorb out 
antibodies against OMPs from hyperimmune rabbit sera and by determining 
the susceptibility of OMPs on intact cells to proteinase K treatment. However, 
serotype 2 strains are not commonly associated with bovine shipping fever 
pneumonia. Furthermore, others have shown that serotype 1 and serotype 2 
P. haemolytica strains are significantly different in their OMP profiles (Davies 
and Donachie, 1996), and that serotype 2 strains are phylogenetically distinct 
from all other P. haemolytica serotypes (Davies et al., 1996). A 
comprehensive analysis of P. haemolytica serotype 1 OMPs, that are both 
surface-exposed and immunogenic, is lacking .. 
Therefore, the purpose of our study was to identify OMPs, produced by a 
bovine isolate of P. haemolytica serotype 1, that are both immunogenic in 
cattle and exposed on the bacterial surface. To identify these OMPs, we 
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utilized a virulent P. haemolytica strain that was isolated from a calf which 
had succumbed to pneumonic pasteurellosis and immune sera from cattle 
that were shown to be resistant to experimental challenge after natural 
exposure to P. haemolytica or after vaccination with P. haemolytica OMPs or 
with live P. haemolytica. We identified surface-exposed, immunogenic 
OMPs that are recognized by all three immune sera and others that are 
recognized by only one or two of these sera. 
Materials and Methods 
Bacterial strain and culture conditions 
P. haemolytica serotype 1, strain 89010807N (Murphy and Whitworth, 
1994) was used in all experiments. Bacteria were cultured in brain heart 
infusion broth (BHI, Difeo Laboratories, Detroit, MI, USA), to the mid-
logarithmic phase, on a rotary shaker (250 rpm) at 370c, unless otherwise 
noted. 
Bovine antisera 
Bovine antisera were collected from calves following natural exposure to 
P. haemolytica (Gentry et al., 1985; Pandher and Murphy, 1996) or after 
subcutaneous vaccination on day O and day 21 with (i) live P. haemolytica (2 
ml of 1 x 109 /ml of 18 hr cultures) or (ii) OMPs (2 mg in 1 ml of phosphate 
buffered saline (PBS) and 1 ml of aluminum hydroxide-ODA-bromide 
adjuvant). This adjuvant was described in Confer et al., 1997. All calves were 
found to be resistant to experimental P. haemolytica challenge (Gentry et al., 
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1985; this study), using a lesion score system previously described by Panciera 
et al., 1984. The calf that was naturally exposed to P. haemolytica exhibited a 
high indirect immunofluorescence titer (>90) to P. haemolytica whole cell 
antigens. The calf was experimentally challenged on day 21 of that 
experiment. The other two calves (OMP and live P. haemolytica vaccinates) 
were part of a separate study and were challenged on day 36. All sera used in 
the study were collected from calves on the day of experimental challenge, 
except the serum from the naturally exposed calf that was used in the 
absorption experiment. Day of challenge (day 21) serum from that calf was 
exhausted during immunoblot analysis of protease treated cells. However, 
serum from the naturally exposed calf, collected on day -4 of that experiment 
was available and was used in the absorption experiment. 
Absorption of antisera with P. haemolytica 
Bovine immune sera were absorbed with intact P. haemolytica using a 
modification of a previously described method (Hansen et al., 1988). P. 
haemolytica, from one liter of culture were pelleted by centrifugation, washed 
once in PBS, and resuspended in immune serum, diluted 1:100 in Tris-HCl 
(10 mM, pH 7.4), NaCl (0.9%), and nonfat dry milk (1 %) (TSM). Cells 
resuspended in serum were incubated at 4°C for 3 hrs on a rocking platform. 
Following incubation, cells were pelleted by centrifugation at 11,000 x g. The 
supernatant was carefully removed and stored at -20°C following the addition 
of sodium azide to 0.02%. Unabsorbed immune sera were used as controls 
and were diluted 1:100 in TSM before use. 
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Protease treatment of intact P. haemolytica 
P. haemolytica (1 ml of mid-log phase culture) were pelleted in a 
microcentrifuge, washed once with 1 ml of suitable enzyme buffer, and 
pelleted again. Cells were resuspended in 250 µ1 of enzyme buffer containing 
50 µg of the appropriate protease (trypsin, chymotrypsin, or staphylococcal VS 
protease; Sigma Chemical Co., St. Louis, MO, USA) and incubated for 1 hr at 
37°C in a shaking incubator. The cells were then pelleted in a 
microcentrifuge, washed once with PBS, and resuspended in 50 µl PBS. For 
controls, cells were incubated in 250 µ1 of enzyme buffer without protease and 
processed in the same manner. Enzyme buffers consisted of: trypsin buffer, 
0.041 M Tris-HCl (pH 8.0), 0.012 M CaCli; chymotrypsin buffer, 0.08 M Tris-
HCl (pH 8.0), 0.1 M CaCl2; Staphylococcal VS protease buffer, 50 m M 
Nli4HC03 (pH 7.8). 
For protease treatment of decapsulated P. haemolytica, capsular 
polysaccharide was removed by incubating cells in PBS at 42°C for 1 hr, as 
described by Gentry et. al (1982). Cells were pelleted in a microcentrifuge and 
processed as described above. 
Western immunoblot analyses 
P. haemolytica whole cell lysates were prepared by incubating the cell 
suspensions in an equal volume of final sample buffer (10% glycerol, 2.5% 
SDS, 0.1 % bromophenol blue, 5% merceptoethanol) at 95°C for 10 minutes. 
Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel 
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electrophoresis (SDS-PAGE) (10%) as previously described (Dabo et al., 1994) 
and transferred to nitrocellulose (MSI, Westboro, MA, USA) using the Trans-
Blot apparatus (BioRad, Richmond, CA, USA), according to the 
manufacturer's instructions. Western blots were probed with bovine antisera 
and bovine IgG was detected as previously described (Dabo et al., 1994). 
Protein relative molecular masses (Mr) were estimated by comparison with 
wide-range protein standards (Novex, San Diego, CA, USA) stained with 
Ponceau S (Sigma). 
Results 
Identification of surface-exposed OMPs by protease treatment 
Surface exposure of P. haemolytica proteins was determined by comparing 
western immunoblots of whole cell lysates from protease-treated cells with 
those from respective buffer-treated controls. Immunoblots were probed with 
antisera from cattle that were resistant to experimental challenge after 
vaccination with P. haemolytica OMPs (Fig. 1), vaccination with live P. 
haemolytica (Fig. 2), or natural exposure to P. haemolytica (Fig. 3). Proteins 
were determined to be surface-exposed if the corresponding band was missing 
or reduced in intensity after protease treatment of intact cells (Table 1). Using 
these methods, we identified 17 distinct proteins as surface-exposed and 
immunogenic. Ten proteins were recognized by all three immune sera. 
Antisera from the live vaccinate recognized two proteins (60 kDa, 76 kDa) that 
were not detected by the other two antisera. The same antisera did not 
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recognize two other proteins (23-24 kDa and 33-34 kDa) that were recognized 
by antisera from both the OMP vaccinate and the naturally-exposed animal. 
Immunogenic proteins with Mrs of 31, 38, and 62 kDa showed only a slight 
decrease or no decrease in intensity after protease treatment of encapsulated P. 
haemolytica but showed a much greater decrease in intensity after protease 
treatment of decapsulated P. haemolytica . 
Identification of surface-exposed OMPs with immune sera absorbed against 
intact P. haemolytica. 
Next, we compared the reactivity of bovine antisera with whole cell 
antigens, before and after adsorption of the immune sera with intact P. 
haemolytica. Antibodies binding to surface-exposed domains on the OMPs 
are depleted from immune sera adsorbed in this manner (Knights et al., 1990). 
When adsorbed sera were used to probe western immunoblots, we observed a 
loss of reactivity or a reduction in reactivity with several P. haemolytica 
antigens (Fig. 4, Table 1). Adsorbed immune sera displayed a complete 
absence of reactivity with some antigens that were detected by unabsorbed 
sera and only a reduction in reactivity with other antigens (25, 28, 32, 33-34, 
and 37 kDa). Some antigens that were identified as surface-exposed by this 




To maximize the number of surface-exposed and immunogenic P. 
haemolytica proteins that we could identify, we (1) performed both protease 
cleavage and antibody absorption assays, (2) used three different proteases for 
analysis, (3) evaluated protease susceptibility in the presence and absence of 
capsular polysaccharide, and (4) probed immunoblots with three different 
bovine immune sera. The immune sera were from (1) a calf vaccinated with· 
live P. haemolytica, (2) a calf vaccinated with P. haemolytica OMPs, and (3) a 
calf naturally exposed to P. haemolytica. We chose the first two antisera 
because vaccination of cattle with live P. haemolytica consistently affords the 
greatest protection against P. haemolytica challenge (Srinand et al., 1995) and 
because vaccination with OMPs (or surface extracts) confers resistance to 
challenge comparable to that observed for vaccination with live P. 
haemolytica (Morton et al., 1995; Srinand et al., 1995). We chose the third 
serum because the immune response that develops from natural exposure to 
P. haemolytica, followed by recovery and resistance to subsequent challenge, 
may differ from that elicited by vaccination and may be superior (Confer, et 
al., 1984. This comprehensive analysis identified 18 P. haemolytica proteins 
that are immunogenic and contain surface-exposed domains. 
Overall, the repertoires of immunoreactive and protease-sensitive bands 
were similar for all three antisera. Likewise, the repertoire of antigens that 
adsorbed out antibodies from the three immune sera. were also similar. 
However, differences in surface protein recognition among the three antisera 
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were evident. The intensity of the iinmunoreactive band at -38 kDa was 
much stronger for sera from the OMP and live vaccinates than for the serum 
from the naturally-exposed calf. However, antibodies against this protein in 
the natural exposure serum were more effectively adsorbed out by whole 
cells. In contrast, the intensities of protease susceptible and immunoreactive 
bands at 24 and 28 kDa were greater for the serum from the naturally-exposed 
animal than for the other two sera. 
When we compare the two methods for assessing surface exposure, 
protease susceptibility and absorption of antibodies, differences are apparent. 
Protease treatment identified 17 of the 18 surface-exposed proteins; whereas, 
antibody absorption with whole cells identified 11 proteins as surface-exposed, 
including one (54 kDa) not identified by protease-treatment. Although cells 
were washed afterward, we have observed that the specific enzyme buffers 
used for protease treatment may affect protein migration. It is probable that 
the 54 kDa protein co-migrated with the non-surface-exposed 55 kDa protein 
on those gels. Several proteins ~ 60 kDa, were cleaved by extracellular 
proteases but did not absorb out antibodies from immune sera. We only 
performed serum absorption studies on logarithmic phase cells, which would 
have been encapsulated (Gentry et al., 1982). It is possible that regions of these 
higher Mr proteins, posses protease cleavage sites extending beyond the 
capsule but lack exposed epitopes that could be recognized by antibodies 
present in the immune sera. 
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The serum concentrations used for the two techniques may also account 
for observed differences in antigen detection. For serum absorption studies, it 
was necessary to dilute the immune sera 1:100 to deplete the surface-reactive 
antibodies with a workable amount of P. haemolytica; whereas, in the 
protease treatment studies the sera were used at a 1:25 dilution. This may also 
explain the lack of reaction with some higher molecular weight proteins (110, 
104, 97, and 76 kDa) in the immunoblots from absorption studies (Fig. 4), that 
are represented by faint bands in the western immunoblots of protease treated 
cells (Figs. 1-3). 
We also observed that the western immunoblot antigen recognition 
profile for the serum from the naturally exposed calf was different in the 
protease treatment studies and serum absorption studies (Figs. 3, 4). The 
western immunoblot for serum absorption analysis revealed a 55 kDa non-
surface-exposed protein that was not present in protease treatment blots .. This 
is likely because the serum used for the protease treatment study was collected 
on day 21 of that experiment, the day of experimental ch~llenge (see Materials 
and Methods). A limited amount of that serum sample was available 
requiring the use of a different serum samples from the same calf ( day -4). for 
the serum absorption study. Interestingly, the loss of an antibody response to 
the 55 kDa antigen in the serum of that calf, which occurred over the 
subsequent 25 days, did not compromise the resistance of the calf to 
experimental P. haemolytica challenge. 
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Our analysis has identified P. haemolytica serotype 1 surface proteins that 
likely correspond to some identified in previous studies, as well as other 
surface proteins not recognized in previous studies. As mentioned earlier,. 
Mosier et al. (1989) identified 13 antigens (16-86 kDa) that were present in a 
saline extract of P. haemolytica and were recognized by at least one of ten 
bovine immune sera that were analyzed. Extract antigens of 31, 34, 38, 49, 51, 
62, 66, and 86 kDa identified in that study are probably analogous to the 31, 34, 
37-38, 47, 54, 62, 66, and 86 kDa proteins that we found to be surface-exposed in 
this study. Using radioiodination, Morton et. al (1996) identified surface-
exposed P. haemolytica serotype 1 proteins of 16, 29.5, 41, 43, 49, 53.5, 84, and 94 
kDa. Our study identified surface-exposed proteins with similar Mrs to all of 
those except the 16 kDa protein, and further demonstrated that they are 
immunogenic in cattle. We identified several surface-exposed proteins that 
were not detected by Morton et. al (1996). This is probably because 
radioiodination is dependent upon the presence of a surface-exposed tyrosine. 
Consequently, a surface-exposed protein without such a residue would go 
undetected. 
Our results include new information that extends the results of previous 
studies. We have identified the repertoire of P. haemolytica serotype 1 
proteins that are both surface-exposed and recognized by immune sera from 
cattle resistant to P. haemolytica challenge. Our analysis identified additional 
such proteins that were not previously recognized in studies which focused 
on identifying surface-exposed proteins (Morton et al., 1996) or immunogenic 
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surface extract proteins (Mosier et al., 1989). Furthermore, our results 
discriminate surface-exposed, immunogenic proteins from cellular proteins 
that elicit an antibody response (Mosier et al., 1989), but may not contain 
surface-exposed regions. Identification of these proteins will allow for more 
detailed analyses on the contribution of the antibody response against specific 
antigens in mechanisms of host defense. 
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Fig. 1. Western immunoblots of P. haemolytica whole cell lysates, prepared 
from protease-treated, encapsulated (capsule +) and decapsulated (capsule -) 
cells. Immunoblots were probed with serum from a calf that was resistant to 
experimental P. haemolytica challenge after vaccination with P. haemolytica 
OMPs. Lanes: T, C, and V are whole tell lysates of P. haemolytica treated with. 
trypsin, chymotrypsin, and staphylococcal V8 protease respectively. Lanes: B, 
whole cell lysates of P. haemolytica treated with respective enzyme buffers 
(negative controls}. 
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Fig. 2. Western immunoblots of P. haemolytica whole cell lysates, prepared 
from protease-treated, encapsulated (capsule+) and decapsulated (capsule -) 
cells. Immunoblots were probed with serum from a calf that was resistant to 
experimental P. haemolytica challenge after vaccination with live P. 
haemolytica. Lanes: T, C, and V are whole cell. lysates of P. haemolytica 
treated with trypsin, chymotrypsin, and staphylococcal VS protease 
respectively. Lanes: B, whole cell lysates of P .. haemolytica treated with 
respective enzyme buffers (negative controls). 
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Fig. 3. Western immunoblots of P. haemolytica whole cell lysates, prepared 
from protease-treated, encapsulated (capsule +) and decapsulated (capsule -) 
cells. Immunoblots were probed with serum from a calf that was resistant to 
experimental P. haemolytica challenge after natural exposure to P. 
haemolytica infection. Lanes: T, C, and V are whole cell lysates of P. 
haemolytica treated with trypsin, chymotrypsin, and staphylococcal VS 
protease respectively. Lanes: B, whole cell lysates of P. haemolytica treated 
with respective enzyme buffers (negative controls). 
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Fig. 4. Western immunoblots of P. haemolytica whole cell lysates probed 
with; OMP, serum from a calf resistant to experimental P. haemolytica 
challenge after vaccination with P. haemolytica OMPs ; Live, serum from . a 
calf resistant to experimental P. haemolytica challenge after vaccination with 
live P. haemolytica; Natural, serum from a cal{ resistant to experimental P. 
haemolytica challenge after natural exposure to P. haemolytica. Lanes: A 
were probed with the immune serum after absorption with intact, 
logarithmic phase P. · haemolytica; U were probed with the unabsorbed serum. 
(negative control). 
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OMP Live Natural 
kDa A U kDa AU kDa A u 
116.3 - 116.3 - 116.3 -
97.4 - 97.4 - 97.4 -- -
66.3 - 66.3- 66.3 -
55.4 - 55.4 - 55.4 -
36.5 - . 36.5- 36.5 -
31 -
31 -
21 .5 - 21 .5 - 21 .5 -
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Table 1. P. haemolytica serotype 1 proteins, recogniz~d by bovine immune 
sera, and identified as surface-exposed after protease treatment analysis and 
immune sera absorption analysis. 
a Whole cell lysates of protease-treated intact P. haemolytica were probed with 
immune sera from calves that were resistant to P. haemolytica challenge 
(Figs. 1-3) 
b Immune sera from cattle resistant to P. haemolytica challenge were absorbed 
with intact P. haemolytica and used to probe P. haemolytica whole cell lysates 
(Fig. 4) 
c Mrs of proteins identified as surface-exposed from Fig. 1. 
d Mrs of proteins identified as surface-exposed from Fig. 2 
e Mrs of proteins identified as surface-exposed from Fig. 3 
* Proteins susceptible to proteases only after removal of capsular 
polysaccharide 
R Proteins that showed a reduction in reactivity with absorbed sera when 
compared to the unabsorbed controls 
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Table 1. P. haemolytica proteins, recognized by bovine immune sera, and identified as surface-
exposed by protease treatment of intact P. haemolytica and immune sera absorption 
analysis. 
Protease Treatments Serum Absorptionb 
Serum Serum 
OMP Live Natural OMP Live Natural 
Vaccinatec Vaccinated Exposures Vaccinate Vaccinate Exposure 
110 kDa 
2 104 kDa 105 kDa 104 kDa 
3 97 kDa 97 kDa 
4 90 kDa 87 kDa 90 kDa 86 kDa 
5 76 kDa 
6 66 kDa 65 kDa 66 kDa 
7 62 kDa* 62 kDa 62 kDa* 0 
8 60 kDa 
00 
9 56 kDa 56 kDa 57 kDa 58 kDa 58 kDa 58 kDa 
10 54 kDa 54kDa 
11 46 kDa 47 kDa 47 kDa 48 kDa 48 kDa 47 kDa 
12 38 kDa* 38 kDa* 37 kDaR 
13 36.5 kDa 36 kDa 36 kDa* 36 kDa 36 kDa 36 kDa 
14 34 kDa 33kDa 34 kDa 33 kDaR 
15 32 kDa 32 kDa 32 kDa* 32 kDaR 
16 31 kDa* 31 kDa* 28 kDa* 28 kDaR 31 kDaR 28 kDaR 
17 26 kDa 26 kDa* 26 kDa 25 kDaR 25kDa 
18 23 kDa 24 kDa* 23 kDa 23 kDa 
CHAPTER III 
GENETIC AND IMMUNOLOGICAL ANALYSES OF A 38 KDA 




Pasteurella haemolytica serotype Al is the bacterial pathogen most 
frequently isolated from the lungs of cattle with bovine respiratory disease. 
As part of a study to. characterize P. haemolytica antigens which are important 
in eliciting resistance to pneumonic pasteurellosis, we have cloned and 
sequenced the gene encoding a 38 kDa lipoprotein, Lpp38. The deduced 
amino acid sequence of :Lpp38 is similar to those of the Escherichia coli 
polyamine transport proteirift PotD ·(70%) and PotF (33%). P. haemolytica 
Lpp38 is present .in both inner membrane and outer membrane fractions. of 
the cen ·· envelope. 
' . . . 
Susceptibility of Lpp38 to cleavage by extracellular 
proteases indicates that portions of the protein are surface-exposed. A protein. 
of similar mol~cular mass in P. haemolytica strains from all 12 serotypes of 
biotype A and iri. an untypeable strain was detected by an anti-Lpp38 
monoclonal antibody. Lpp38 is recognized by sera from calves resistant to 
infection after natural exposure to P. haemolytica and by sera from calves 
protected against infection by vaccination with P. haemolytica Al outer 
membranes or with live bacteria. These data suggest a role for this protein in 
the development of immunity to P. haemolytica infection. 
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Introduction 
Pasteurella haemolytica biotype A serotype 1 is the bacterium most 
commonly associated with shipping fever or pneumonic pasteurellosis, a 
disease of beef cattle characterized by a fibrinous pleuropneumonia (reviewed 
.· . 
in Frank, 1989). Currently available commercial vaccines for the prevention 
of bovine pneumonic pasteurellosis consist of P. haemolytica bacterins, 
attenuated live P. haemolytica, cell . extracts, or culture supernatant 
preparations (Confer, 1993). Many experimental vaccine formulations and 
those currently available commercially have proven to be largely ineffective 
or of limited effectiveness in eliciting protection. 
Several .studies indicate that P. haemolytica outer membrane proteins 
(OMPs) are among the most important antigens in stimulating resistance to 
pneumonic pasteurellosis (Morton et al., 1990, 1994, 1995; Mosier et al., 1989; 
reviewed in Confer, 1993). Mosier et al. (1989) demonstrated a statistically. 
significant correlation between resistance to pneumonic pasteurellosis and 
the presence of serum antibodies (Abs) directed against several proteins 
present in a saline. extract of whole P. haemolytica. More re_cently, cattle 
were shown to be resistant to experimental P. haemolytica challenge after 
immunization with sarkosyl insoluble OMPs. (Morton et al., 1995); In that 
study, antibodies against OMPs with relative molecular masses (Mr) of 16.5, 
37, 45.5, 50.5, and 84.5 kDa were shown to correlate significantly with this 
resistance (Morton et al., 1994). 
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The purpose of this study was to examine the specific nature of the 
immunogenic P. haemolytica OMP of approximately 37 kDa. We have cloned 
and sequenced the gene which encodes a surface-exposed, immunogenic OMP 
with a predicted Mr of 38 kDa. Using sera from cattle vaccinated with various 
P. haemolytica antigen preparations, we also demonstrate that this protein is 
the major immunogenic P. haemolytica OMP in the Mr range of 35-40 kDa. 
Materials and methods 
Bacterial strains, bacteriophage, and culture media 
Escherichia coli DH5a and P. haemolytica serotype Al Oklahoma strain 
(OK) (Newman et al., 1982} and strain 89010807N (Murphy and Whitworth, 
1994) were grown as previously described (Murphy and Whitworth, 1994). P. 
haemolytica biotype A type strains were a gift of Glynn H. Frank (USDA, 
NADC, Ames, Iowa) and were grown as were serotype Al strains. E. coli BB4 
and XLl-Blue and bacteriophage AZAPII and R408 were supplied with a 
chromosomal library (Clontech Laboratories, Inc., Palo Alto, Calif.) and were 
grown according to the manufacturer's instructions. When appropriate, 
ampicillin (50 µg/ml) was added to media. 
P. haemolytica genomic library, gene cloning, and DNA analyses 
Chromosomal DNA was isolated from P. haemolytica 89010807N as 
described (Murphy and Whitworth, 1994), and a genomic library was prepared 
at Clontech Laboratories, using the bacteriophage vector AZAPII. The P. 
haemolytica chromosomal library was screened immunologically with 
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pooled monoclonal antibodies (produced as described below), and reactive 
phage were purified according to the manufacturer's instructions. Plasmid 
DNA (pBluescript) carrying the cloned DNA insert was excised from 
recombinant 11.,ZAPII bacteriophages according to the manufacturer's 
instructions. Plasmids were purified with the Magic system (Promega Corp., 
Madison, Wisc.) or the Qiagen system (Qiagen Inc., Chatsworth, Calif.). 
Cloned DNA inserts in recombinant plasmids were sequentially deleted from 
each end with the Erase-A-Base System (Promega). The subsequent 
recombinant plasmids were purified (Qiagen) and both strands of insert DNA 
were sequenced at the OSU Recombinant DNA/Protein Resource Facility, on 
an Applied Biosystems Inc. (Foster City, Calif.) 373A automated DNA 
sequencer. DNA sequences were assembled and analyzed with Assemblylign 
and MacVector DNA analysis software (Eastman Kodak Co., New Haven, 
Conn.). 
Antigen preparation and analysis 
P. haemolytica cell envelopes were prepared as previously described 
(Simons et al., 1989). Envelopes were extracted with an equal volume of 0.5% 
sarkosyl (N-lauryl sarcosine (Sigma Chemical Co., St. Louis, Mo.)) for 30 min 
at room temperature. Sarkosyl insoluble, OMPs were collected by 
centrifugation at 200,000 x g for 70 min. The supernatant contained sarkosyl 
soluble, inner membrane proteins. Protein concentrations were estimated 
with BioRad (Richmond, Calif.) or BCA (Pierce, Rockford, Ill.) protein assay 
kits. Whole cell lysates were prepared by resuspending 2 ml of cells grown to 
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stationary phase in 0.2 ml PBS and 0.2 ml final sample buffer (10% glycerol, 
2.5% SDS, 0.1 % bromophenol blue, 5% b-mercaptoethanol) and heating at 
95°C for 5 min. Proteins in whole cell lysates, cell envelopes, and membrane 
fractions were separated by SDS-PAGE (10% or 12.5%) as previously described 
(Dabo et al., 1994). 
Monoclonal Antibody Production 
Monoclonal antibodies (MAbs) were prepared by the Oklahoma State· 
University Hybridoma Center for Agricultural and Biological Sciences 
(Stillwater, Okla.) according to published methods (Bandla et al., 1993; 
Sherwood et al., 1987), by injection of mice with gel-purified protein as 
previously described for MAb 6A6Cll (Murphy and Whitworth, 1994). 
Bovine antisera 
Bovine antisera were kindly provided by Anthony W. Confer (OSU, 
Stillwater, Okla.). Sera were collected from calves shown to be resistant to 
experimental challenge with P. haemolytica Al and were from three sources 
(i) animals naturally exposed to P. haemolytica [determined by high indirect 
immunofluorescence titers {>90}] (Gentry et al., 1985); (ii) animals vaccinated 
with live P. haemolytica Al (Morton et al., 1995); and (iii) animals vaccinated 
with the sarkosyl insoluble outer membrane fraction of P. haemolytica Al 
(Morton et al., 1995). Vaccinated calves received two subcutaneous injections, 
on day O and day 7, of either 2 ml of live P. haemolytica Al (1 x 109 /ml) or 2 
ml of OMP preparations (2.0 mg/ml) mixed with an equal volume of 
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Freund's incomplete adjuvant (Morton et al., 1990, 1995). All sera used were 
collected on day 21, the day of experimental challenge. 
lmmunoblot analyses 
For western immunoassays, proteins were transferred to nitrocellulose 
(MSI, Westboro, Mass. or BioRad Laboratories) using the Trans-blot apparatus 
(BioRad), according to the manufacturer's instructions. Western 
immunoblots with bovine sera were performed as previously described (Dabo 
et al., 1994). For MAb probing, blots were blocked with 1 % non-fat dry milk 
(BioRad) in PBS with 0.02% sodium azide, washed in 0.01 M Tris-HCl, 0.2 M 
NaCl, pH 7.4 with 0.05% bovine serum albumin (BSA), incubated with MAb 
(hybridoma culture supernatant) diluted 1:25 in PBS/sodium azide. 
Immunoreactive bands were detected with alkaline phosphatase-conjugated, 
goat anti-mouse IgG (Sigma), and filters were developed in 5-bromo-4-chloro-
3-indolyl phosphate/nitro blue tetrazolium solution (Sigma). 
[3H]-palmitic acid labeling of bacteriallipoproteins 
Lipoproteins of logarithmic phase P. haemolytica Al or E. coli harboring 
recombinantplasmids were radiolabeled with [9,l0-3H]-palmitic acid (Dupont, 
NEN, Boston, Mass.) and analyzed as described previously (Dabo et al., 1994). 
Protease treatment of whole cells 
. . 
P. haemolytica or E .. coli cells G ml), in the mid-logarithmic phase of 
growth, were collected by centrifugation and washed in an equal volume. of: 
the appropriate enzyme buffer. Cells were resuspended in 0.25 ml of enzyme 
buffer, and 50 mg of enzyme in 0.005 ml was added. Negative controls 
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received an equal volume. of enzyme buffer with no enzyme. Cells were 
incubated on a rotary shaker (120 rpm) for 1 hr at 37°C, collected by 
centrifugation and washed with 1 ml of PBS. Cells were resuspended in O;OS 
ml PBS and 0.05 ml final sample buffer and heated at 95°C for 5 min before 
SOS-PAGE analysis. For protease treatment of de-capsulated P. haemolytica, 
capsule was removed by incubating cells in PBS for 1 hr at 42°C, as described 
previously (Gentry et al.; 1982). Trypsin, chymotrypsin, and Staphylococcal 
V8 protease (Sigma) were used for protease treatment of whole cells. Trypsin 
digests were performed in 0.041. M Tris-HCl (pH 8.0), 0.012 MCaClz. 
,. 
· Chymotrypsin digests were performed_ in 0.08 M Tris-HCl (pH 8.0), 0.1 M 
CaClz. Staphylococcal V8 protease digests were performed in PBS (pH 8.0). 
GenBank accession number 
The GenBank accession number for the nucleotide sequence of lpp38 is 
U25682. 
Results 
Mol~cular cloning and DNA sequence of lpp38 
We screened a 1ZAPII library of P. haemolytica chromosomal DNA with a 
panel of MAbs against a 38 kDa membrane protein and identified three 
recombinant phage which bound the MAbs. Recombinant plasmids were 
excised from phage DNA and transformed into E.coli (XLl-Blue). Restriction 
-enzyme mapping revealed that the DNA inserts in all three plasmids were 
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identical. Therefore, one recombinant clone, E. coli (pKP420), was chosen for 
further study. 
To cbmpare the size of the recombinant protein expressed in E. coli with 
that expressed by P. haemolytica, we probed a western immunoblot of E. coli 
whole cell lysates and P. haemolytica outer membrane and inner membrane 
fractions with the MAb 6A6E5g (Fig. 5). The MAb recognized a protein of the · 
same Mr in E.coli (pKP420) and in both P. haemolytica membrane fractions. 
A slightly larger immunoreactive band was also present in the recombinant 
clone. 
DNA sequencing of the cloned insert revealed an open reading frame 
capable of encoding a protein of 364 amino acids (40.144 kDa) (Fig. 6). The 
deduced amin9 · acid sequence of the protein contains a presumptive signal 
peptide and a .consensus. lipoprotein processing site. The Mr of the putative 
mature form of the lipoprotein, after cleavage of the signal peptide, is 38 .. 3 
kDa. We have designated this gene as lpp38 and the protein encoded by the 
gene as Lpp38. A search of the GenBank DNA sequence databank revealed 
similarities between the deduced amino acid sequence of Lpp38 and two E. 
coli proteins, the polyamine transport protei11 PotD and the putrescine 
transport protein PotF. The sequence of Lpp38 is 50°/o identical to PotD and 
17% identical to PotF. When conservative amino acid substitutions are 
included, Lpp38 is 70% similar to PotD and 33% similar to PotF (Fig. 7). 
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Lipid modification of the protein 
To determine if this protein is actually lipid-modified, we compared total 
cellular lipoproteins from P. haemolytica, recombinant E. coli (pKP420), and 
non-recombinant E. coli after growth in the presence of [3H]-palmitic acid. As 
. shown in Fig. 8, whole cell ly~ates of E. coli (pKP420) contain a lipoprotein 
which migrates at the same Mr as one produced by P. haemolytica (-38 kDa). 
This lipoprotein: is absent in non'.'"recombinant E. coli. 
Reactivity of bovine immunesera with Lpp38 
Morton et al., (1994, 1995) have shown that sera from calves resistant to P. 
haemolytica challenge react with a protein of similar Mr as Lpp38. Those 
studies examined sera from (1) .calves vaccinated with live P. haemolytica and 
(2) calves vaccinated with P. haemolytica OMPs .. Here, we used those same 
sera to examine the immunological response of calves to Lpp38. We also 
used sera from calves that were found to be resistant to P. haemolytica 
infection after natural exposure to P. haemolytica (Gentry et al., 1985). By 
western immunoblot analysis, sera from . these calves all · recognized a P. 
haemolytica membrane protein of approximately 38 kDa, which migrated at 
the same Mr as recombinant Lpp38 produced by E. coli (pKP420) (Fig. 9). All 
the sera also recognized rLpp38 (Fig. 5 and data not shown). 
Conservation of the protein among biotype A strains of P. haemolytica 
To determine if Lpp38 is produced by other P. haemolytica serotypes, we 
examined whole cell lysates of all biotype A strains and one untypeable strain 
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by western immunoblot analysis. The anti-Lpp3S MAb 6A6Cll recognized a 
band of similar Mr in all these strains (data not shown). 
Analysis of surface exposure of Lpp38 
Regions of Lpp3S which are exposed on the surface of P. haemolytica may 
be targets· for Ab-dependent immune mechanisms of the bovine host. To 
determine the presence of surface-exposed regions of Lpp3S, we treated P. 
haemolytica, with and without intact capsule, arid E. coli (pKP420) with three 
proteases and examined treated cells for alterations in the size of the anti- . 
Lpp3S MAb-reactive band. Whole cell lysates of protease~treated cells were 
examined by western immunoblot analysis with the. anti-Lpp3S MAb 6A6E5y 
(Fig. 10). Trypsin treatment of encapsulated and de-c'l:1.psulated P. haemolytica 
resulted in the appearance of two MAb-reactive bands, one faint band with 
the same Mr as Lpp3S and a more strongly reactive band with a slightly 
smaller Mr. Chymotrypsin and Staphylococcal VS protease treatment of 
· encapsulated P. haemolytica resulted in no change to Lpp3S. However, 
treatment of de-capsulated P. haemolytica with those enzymes resulted in a 
marked reduction of the intensity of the Lpp38 band and the appearance of 
fainter bands of lower Mr. Treatment of recombinant E. coli with trypsin lead 
to changes in Lpp3S similar to those observed with P. haemolytica, but 
chymotrypsin and Staphylococcal VS protease treatment of E. coli (pKP420) 
did not result in cleavage of rLpp3S (data not shown). 
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Discussion 
In this study, we have cloned and sequenced a gene encoding an antigenic 
38 kDa lipoprotein of P. haemolytica Al. The deduced amino acid sequence of 
this lipoprotein, Lpp38, is similar to that of the E. coli polyamine binding 
protein PotD (Furuchi et al., 1991) and to a lesser extent that of the E. coli 
putrescine transport protein PotF (Pistocchi et al.,· 1993). However, significant 
differences between Lpp38 and the E. coli proteins are apparent. Unlike 
Lpp38, the PotD and PotF amino acid sequences do not appear to possess the 
typical Gram-negative lipoprotein processing site. · Analyses of the N -
terminal amino acid sequences of PotD and PotF reveled that these proteins 
are apparently not lipid-modified in E. coli (Furuchi et al., 1991), and cell 
fractionation studies revealed· that both are present in the periplasm of that 
organism. The potD gene is the terminal gene in an operon of four genes 
(potA, potB, potC, potD) all of which encode proteins involved in the uptake 
of polyamines. Here, we did not observe open reading frames 5' of lpp38 
which would correspond to E. coli potA, potB, or potC. 
By western immunoblot analysis, we detected Lpp38 in both sarkosyl 
soluble and sarkosyl insoluble fractions of the P. haemolytica cell envelope. 
This result is consistent with our previous observations of other P. 
haemolyticti ,membrane lipoproteins. We have found that an individual P. 
haemolytica lipoprotein may be present in both inner and outer membrane 
fractions purified by sarkosyl solubilization or on sucrose density gradients. 
Others have reported similar observations with lipoproteins in membrane 
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fractions purified on sucrose density gradients (Cooney and Lo, 1993). 
Preparation of P. haemolytica membrane fractions by sarkosyl solubilization 
results in an almost identical protein profile by SDS-PAGE and distribution of 
membrane markers (2-keto-3..;deoxyoctonate (KDO), succinate dehydrogenase) 
as does preparation by sucrose density gradient centrifugation (Confer et al., 
1995; Squire et al., 1984; data not shown). Neither method appears capable of 
determining the exact membrane location of P. haemolytica lipoproteins. 
Recent studies with other Gram-negative bacteria . have indicated that 
lipoproteins may be associated with intermediate density membrane material 
which contains both inner membrane and outer membrane marker proteins 
and may be derived from a cell envelope region in which the two membranes 
are in intimate contact (Poquet et al., 1993). Others have also suggested 
numerous potential conformations for lipoproteins in the Gram-negative . · 
bacterial membrane (Pugsley, 1993). 
Nevertheless, the accessibility of Lpp38 to proteases, upon treatment of 
· intact P. haemolytica, suggests that at least a portion of this protein is exposed 
· on the bacterial cell surface. Similar results with the· recombinant form of the 
protein in E. coli indicate that · Lpp38 assumes the. same or a very similar 
conformation in the E. coli ceU membrane as it does in the P. haemolytica 
membrane. We also found that the anti-Lpp38 MAb detected a protein of 
slightly larger Mr in E.coli than the band which represented the mature form 
of Lpp38 in P. haemolytica and E.coli. We believe that this band represents 
the precursor form of Lpp38 which is incompletely processed in E. coli. This 
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. hypothesis is supported by the observation that the band of larger Mr is not 
labeled with [3H]-palmitic acid (Fig. 7, lane 2). 
The western immunoblot assays with sera from calves naturally exposed 
to P. haemolytica or exposed by vaccination demonstrated that Lpp38 is 
immunogenic. Similar assays performed on E. coli with and without pKP420 
verified that Lpp38 is indeed the protein recognized by those sera (Fig. 9, lanes 
1-2, and data not shown). It is of interest that the calves, whose sera were. 
used in our experiments, were shown to be resistant to transthoracic 
experimental challenge with P. haemolytica (Morton et al., 1995). As part of 
that study, ·Morton et al. . (1995) also demonstrated that vaccination with P. 
haemolytica OMPs elicited an antibody response, against a 37 kDa OMP, 
which correlated statistically with resistance to experimental challenge. Our 
data (Fig. 9) indicate that Lpp38 is the major· immunogenic P. haemolytica Al 
membrane protein migrating at an Mr of 37-38 kDa. Therefore, it is probable 
that Lpp38 represents the 37 kDa protein identified by Morton et aL (1995). 
The conservation of this protein among different P: haemolytica serotypes 
. may also aid in resistance to infection with heterologous strains. 
Proteins exposed on the bacterial cell surface are potential targets of the 
host immune response. Two important mechanisms of bovine immunity to 
P. haemolytica, complement-mediated killing and neutrophil-mediated 
phagocytosis, are further enhanced by opsonization of the bacteria (Chae et al., 
1990; Czuprynski et al., 1987) and by removal of capsule (Chae et al., 1990). 
The antigenic nature of Lpp38 in cattle naturally exposed to P. haemolytica or 
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cattle vaccinated with various antigen preparations suggests a possible role for 
Abs against this protein in immunity. Although both complement-mediated 
killing and neutrophil phagocytosis of P. haemolytica have. been shown to be 
more effective in the absence of capsule, the cleavage of Lpp38 by extracellular 
protease even in the presence of the bacterial capsule, indicates that regions of 
the protein are accessible to antibody binding. The role of Abs against Lpp38 
in these immune processes is currently under investigation. 
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Fig. 5 Western immunoblot of P. haemolytica outer membrane and inner 
membrane fractions and E. coli whole cell lysates probed with the anti-Lpp38 
MAb, 6A6E5y. Lanes: 1, E.coli XLl-Blue (pBluescript), non recombinant; 2, E. 
coli XLl-Blue (pKP420); 3, P. haemolytica Al outer membrane; 4, P. 
haemolytica Al inner membrane. 
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Fig. 6 Nucleotide sequence of the gene encoding Lpp38. The deduced a:rnino 
acid sequence is shown beneath the nucleotide sequence. The location of 
putative promoter sequences (-35 and -10) are underlined. The putative 
ribosome binding site is also underlined. Putative sequence motifs were 
determined based, ·upon comparison with · consensus sequences and the 
presence of appropriate nucleotide spacing, using the MacVector (Eastman 




M K K L A G L F A A G L A T V A L T A C N E E K A A 
201 GAGCCAAAAGCAACTGCGGCTGAAGCAAAACCTCAAGCAACAAATCAAACAGTTCACCTTTATACTTGGACTGAATATGTGCCTGAAGGTTTGTTAGAT 
E P K A T A A E A K P Q A T N Q T V H L Y T W T E Y V P E G L L D 
300 GAATTTACGAAAGAAACCGGCATTAAAGTTGAAGTTTCAAGTCTTGAATCTAACGAAACAATGTACGCTAAATTAAAATTACAAGGCAAAGATGGCGGT 
E F T K E T G I K V E V S S L E S N E T M Y A K L K L Q G K D G G 
399 TATGATGTAATTGCTCCATCAAACTACTTTGTATCTAAAATGGCGAAAGAAGGAATGTTAGCGGAATTAGATCACGCACAACTTCCGGTTATTAAAGAA 
Y D V I A P S N Y F V S K M A K E G M L A E L D H A Q L P V I K E 
498 TTAAACCAAGATTGGTTAAATAAACCTTACGATCAAGGAAACAAATATTCATTACCTCAATTATTAGGTGCGCCGGGTATTGCATTTAATACGGCAGAT 
L N Q D W L N K P Y D Q G N K Y S L P Q L L G A P G I A F N T A D 
597 TACAAAGGTGAAACATTCACTTCTTGGGGTGATTTGTGGAAACCTGAATTTGCAGGTAAAGTACAATTATTAGATGATGCTCGTGAAGTATTCAACATT 
Y K G E T F T S W G D L W K P E F A G K V Q L L D D A R E V F N I 
696 GCGTTATTAAAATTAGGTAAAAACCCAAATACAACTAATCCGGATGAAATCAAAGAAGCCTTTGAAGAGTTGAAAAAATTACGTCCAAATGTGCTTTCA 
A L L K L G K N P N T T N P D E I K E A F E E L K K L R P N V L S 
795 TTTACCTCTGATAACCCGGCAAACTCATTTATTGCTGGTGAGGTTTCTGTAGGTCAGTTATGGAACGGTTCTGTACGTATTGCGAAGAAAGAAAACGCA 
F T S D N P A N S F I A G E V S V G Q L W N G S V R I A K K E N A 
894 CCGGTTGATATGGTATTCCCGAAAGAAGGTCCTGTGCTTTGGGTCGATACTTTAGCCATTCCGGCAAATGCGAAAAACAAAGAAAATGCACATAAATTA 
P V D M V F P K E G P V L W V D T L A I P A N A K N K E N A H K L 
993 ATCAACTACTTATTAAGTGCAAAAGTAGCTGAAAAATTAACGTTAGCGATTGGTTACCCAACTTCAAACGTAGAAGCATTAAAAGTATTACCGAAAGAA 
I N Y L L S A K V A E K L T L A I G Y P T S N V E A L K V L P K E 
1092 ATTACTGAAGATACAGCAATTTACCCATCTGCAGAGGTTTTACAAAAATCTCAATGGCAAGATGATGTTGGTGATGCAATTGAGCTTTACGAAAAATAC 
I T E D T A I Y P S A E V L Q K S Q W Q D D V G D A I E L Y E K Y 
1191 TACCAAGAGTTAAAAGCAGCAAAATAATGCGTGATT 




Fig. 7 Alignment of the deduced amino acid sequences of P. haemolytica 
Lpp38 and the E. coli proteins PotD and PotF. Numbering corresponds to the 
Lpp38 sequence. The location of the presumptive signal peptide of Lpp38 is 
shown. The * indicates the amino terminal, lipid-modified cysteine of the 
mature lipoprotein, Lpp38. Amino acids in bold type are those in Lpp38 
which are identical with either PotD or PotF. 
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~-signal peptide~~* 
Lpp38 .••. l.MKKLAG-LFAAG-LATVALTACNEEK-AAEPKATAAEAKPQATNQTVHLY'IWTEYVPEGLLDEFTKETGIKVEVSSLESNETMYA 
PotD .•....• MKKWSRHLLAAGALALGMSAAHADDNN------------------TLYFYNWTEYVPPGLLEQFTKETGIKVIYSTYESNETMYA 
PotF ...•... MTALNKKWLS-G-LVAGALMAVSVGTLAAEQK-TLHIYNWSDYIAPD-----T--VAN-----FEKETGIKVVYDVFDSNEVLEG 
Lpp38 ... 82.KLKLQGKDGGYDVIAPSNYFVSKMAKEGMLAELDHAQLPVIKELNQDWLNKPYDQGNKYSLPQLLGAPGIAFNTAYKGETF-TSW 
PotO .•..••. KLKTY-KDGAYDLVVPSTYYVDKMRKEGMIQKIDKSKLTNFSNLDPDMLNKPFDPNNDYSIPYIWGATAIGVNGDAVDPKSVTSW 
PotF ...•.•. KLMAGSTGFDLVVPSASFLERQLTAG-VFQP-LDKSKLPEWKNLDP-ELLKLVD--NKFAMPYMWATTGIGYNVDKVKAVLGENA 
Lpp38 .. 166.GDDLWKPEFAGKVQLLDDAREVFNIALLKLGKNPNTTNPDEIKE-AFEELKKLRPNVLSFTSDNPANSFIAGEVSVGQLWNGSVR 
Poto ••••.•. -ADLWKPEYKGSLLLTDDAREVFQMALRKLGYSGNTTDPKEI-EAAYNELKKLMPNVAAFNSDNPANPYMEGEVNLGMIWNGSAF 
PotF ••.••.. -PVDSW-DLILKPENLEKLKSCGVSFLDAPEEVF-ATVLNYLGKDPNSTKADDYTGPATDLLLNVRPNIRYFHSSQYINDLANGD 
Lpp38 .. 250.I----------------AKKENAPVDMV-F--PKEGPVLWVDTLAIPANAKNK-ENAHKLINYLLSAKVAEKLTLAIGYPTSNVE 
Poto •..•..• v----------------ARQAGTPIDVVW---PKEGGIFWMDSLAIPANAKNK-EGALKLINFLLRPDVAKQVAETIGYPTPNLA 
PotF .....•. ICVAIGWAGDVWQASNRAKEAKNGV-NVSFSIPKEGAMAFFDVFAMPADAKNKDE-AYQFLNYLLRPDVVAHISDHVFYANANKA 
Lpp38 .. 266.ALKVL-PKEITEDTAIYPSAEVLQKSQ-WQDDVGDAIELYEKYYQELKAAK 
PotD •.•.•.. ARKLLSP-EVANDKTLYPDAETI-KNGEWQNDVGAASSIYEEYYQKLKAGR 
PotF .••••.. ATP-LVSAEVRENPGIYPPADVRAKLFTLK--VQDPKIDRVRTRAWTK-VKS 
II") 
0 -
Fig. 8 Autoradiogram of SDS-polyacrylamide gel with 3H-palmitic acid-
labeled total cellular lipoproteins. Lanes: 1, E. coli DH5a (pBluescript), a non-
recombinant strain; 2, E. coli DH5a (pKP420), a recombinant carrying the P. 
haemolytica lpp3 gene; 3, P. haemdlytica Al 89010807N. Lpp38 is indicated 
with an arrowhead. 
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Fig. 9 Western immunoblot of P. haemolytica cell envelope fractions and E. 
coli whole cell lysates probed with bovine sera. Lane: 1, non recombinant E. 
coli XLl-Blue; 2, E. coli XLl-Blue (pKP420); 3 - 7, P. haemolytica cell envelopes. 
Lanes 1 - 3 were probed with serum from a calf vaccinated with live P. 
haemolytica. Lanes 4 - 5 were probed with sera from calves vaccinated with 
outer membranes of P. haemolytica. Lanes 6 - 7 were probed with sera from 
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Fig. 10 Western immunoblots of P. haemolytica whole cell lysates prepared 
after treatment of intact cells with various proteases. The blot was probed 
with the anti-Lpp38 MAb 6A6Cll. Lanes: 1-6, decapsulated P. haemolytica 
treated with; 1, Staphylococcal V8 protease buffer; 2, Staphylococcal V 8 
protease; 3, chymotrypsin buffer; 4, chymotrypsin; 5, trypsin buffer; 6, trypsin. 
Lanes: 7-12 intact (encapsulated) P. haemolytica treated with; 7, 
Staphylococcus V8 protease buffer; 8, Staphylococcus V8 protease; 9, 
chymotrypsin buffer; 10, chymotrypsin; 11, trypsin buffer; 12, trypsin. 
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CHAPTER IV -
GENETIC AND IMMUNOLOGIC ANALYSES OF PlpE, A 
LIPOPROTEIN IMPORTANT -IN COMPLEMENT-MEDIATED 
KILLING OF Pasteurella haemolytica Sl 
112 
Abstract 
Pasteurella haemolytica Sl is the organism most commonly associated 
with bovine shipping fever pleuropneumonia. Antibodies against outer 
membrane proteins (OMPs) of P. haemolytica have been correlated with 
development of resistance to the disease. In this manuscript, we present 
research on an immunogenic, surface-exposed OMP of P. haemolytica, PlpE. 
We affinity-purified antibodies against PlpE from bovine immune serum and 
used these antibodies to clone the gene encoding PlpE. DNA sequencing and 
analysis of the deduced amino acid sequence revealed that PlpE is a 
lipoprotein and that it. is similar to Actinobacillus pleuropneumoniae 
lipoprotein, OmlA. Vaccination of pigs with OmlA from serotype 1 has been 
shown to enhance protection of pigs against homologous A. 
pleuropneumoniae challenge. Anti-PlpE antibodies recognize a protein of 
same or different molecular weights in all serotypes of P. haemolytica except 
serotype 11. Our data suggest that PlpE and recombinant PlpE are surface-
exposed in P. haemolytica and E. coli, respectively. We used intact 
recombinant E. coli that express PlpE, to adsorb out PlpE-reactive antibodies 
from bovine immune serum. In an assay measuring the complement-
mediated killing of P. haemolytica, serum depleted of antibodies specific for 
PlpE, by absorption with intact recombinant E. coli, had a significant reduction 
in bacterial killing as compared to the same serum absorbed with non-
recombinant E. coli. Our data indicates that PlpE is an important immunogen 
of P. haemolytica and a favorable candidate for a sub-unit vaccine. 
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Introduction 
Pasteurella haemolytica serotype 1 (Sl) is the organism most commonly 
associated with shipping fever, a disease of beef cattle characterized by 
fibrinous pleuropneumonia (Frank, 1989). The disease is of significant 
economic importance to the beef industry in the USA, amounting to annual 
losses approaching 1 billion dollars (Dee, 1997). Shipping fever pneumonia is 
precipitated by stress inducing conditions such as shipping, viral infections,. 
inhalation of diesel fumes, overcrowding, and weaning (Confer et al., 1988) .. 
P. haemolytica Sl reside. in low numbers in the upper respiratory tract of 
cattle and und~r stressful conditions they proliferate and are aerosolized, in 
large numbers, into lung alveoli where they cause the disease (Frank and 
Briggs, 1992). 
Numerous surface and secreted molecules of P. haemolytica Sl have been 
studied to evaluate their roles in immunity to P. haemolytica infection· 
(reviewed in (Confer, 1993)). Included among these are P. haemolytica outer 
membrane proteins (OMPs) (Squire et al., 1984; Sreevatsan et al., 1996; Confer 
et al., 1990). Vaccination of cattle with an OMP-enriched fraction of P. 
haemolytica cell envelopes. significantly reduced lung damage following 
experimental challenge with P. haemolytica (Morton· et al., 1995). Statistical 
correlations have been demonstrated between resistance to pneumonia and 
the bovine antibody response to proteins present in surface extracts of P. 
haemolytica (Confer et al., 1989; Sreevatsan et al., 1996). Several studies have 
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analyzed the bovine antibody response that develops after vaccination with P. 
haemolytica antigens or after P. haemolytica infection, to purified individual 
OMPs including a 94 kDa membrane protein (Nelson and Frank, 1989) and 
PomA, a protein belonging to the OmpA family, (Mahasreshti et al., 1996). 
We and others have cloned and sequenced genes encoding P. haemolytica 
OMPs and examined the bovine antibody response to the recombinant 
proteins, including several membrane lipoproteins (Craven et al., 1991; 
Cooney and Lo, 1993; Dabo et al., 1994; Pandher and· Murphy, 1996). These 
· studies suggest a role for outer membrane antigens in eliciting protective 
immunity.' However, the capacity for P. haemolytica OMP-specific antibodies, 
to function in host defense mechanisms remains uncharacterized. For the 
development of more effective vaccines, it will be important to characterize 
individual OMPs and identify those that elicit host antibodies that enhance 
resistance to P. haemolytica infection. 
Complement-mediated lysis is an important host-defense mechanism 
against microbial infection and is believed to play a role in controlling P. 
haemolytica pneumonia. Serum complement concentrations were found to 
be lower in stressed cattle after transport to a feedlot (Purdy et al., 1991). 
Lower complement concentrations were associated with higher morbidity in 
the feedlot, and morbid calves had significantly lower complement levels 
than did healthy calves in the same feedlots (Purdy et al., 1991). These data 
suggest that a decrease in serum complement levels might facilitate P. 
haemolytica infection. However, complement-mediated killing of P 
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haemolytica requires sensitization with antibodies (MacDonald et al., 1983). 
Antibodies against surface-exposed epitopes of OMPs can function as 
opsonins as well as they are likely to play an important role in complement-
mediated lysis of P. haemolytica. 
Cattle that are resistant to P. haemolytica-induced pneumonia develop 
antibodies to a surface-exposed, -45kDa OMP (chapter 1). The purpose of this 
study was to determine, through genetic cloning and DNA sequencing, the 
specific identity of the immunogenic 45 kDa protein and to evaluate the 
contribution of antibodies against this protein, to complement-mediated 
killing of P. haemolytica. We have found that the 45 kDa protein is a 
lipoprotein, designated PlpE, and that antibodies against PlpE, present in 
bovine immune sera, contribute to complement-mediated killing of P. 
haemolytica. 
Materials and Methods 
Bacteria, bacteriophage, culture media, and genomic library 
P. haemolytica (89010807N) serotype 1 was grown in BHI broth or on BHI 
agar (Difeo Laboratories, Detroit, MI, USA) as previously described (Murphy 
and Whitworth, 1994). Escherichia coli strains BB4 and XLl-Blue and 
bacteriophages lambda ZAPII and R408 were supplied with a P. haemolytica 
genomic DNA library (Clontech Laboratories, Palo Alto, Calif.) (Pandher and 
Murphy, 1996) and were grown according to the manufacturer's instructions. 
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Recombinant E. coli were always grown in the presence of ampicillin (50 
µg/ml). 
Bovine immune sera and purification of antibodies 
Two bovine immune sera were used, one from a calf hyperimmunized 
with live P. haemolytica (Lessley et al., 1985) and one from a calf that was 
vaccinated with P. haemolytica OMPs and was resistant to experimental P. 
haemolytica challenge (Confer et al., unpublished data). Antibodies against P. 
haemolytica -45 kDa OMPs were purified from the bovine hyperimmune 
serum by an immunoaffinity procedure (Harlow and Lane, 1988). P. 
haemolytica outer membranes were purified as described previously (Simons 
et al., 1992), separated by preparative SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) (Dabo et al., 1994), and transferred to nitrocellulose membranes 
(Pandher and Murphy, 1996). The region of the nitrocellulose membrane 
containing -45 kDa proteins was identified by comparison with pre-stained 
molecular weight standards (BioRad Laboratories, Richmond, Calif.) on the 
membrane. The 45 kDa region of the nitrocellulose was excised and 
incubated for 1 hr with the bovine hyperimmune serum (1:25) in 0.01M Tris-
HCl (pH 7.4), 0.2M NaCl, (TS) containing 0.05% gelatin and 0.05% Tween 
(TSGT). Nitrocellulose strips were washed with TS, 3 x 5 min. Anti-45 kDa 
antibodies bound to antigen on the nitrocellulose strips were eluted as 
described (Harlow and Lane, 1988). The eluted antibodies were concentrated 
using a Centriprep 10 concentrator (Amicon Inc., Beverly, Mass.). 
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Gene cloning, DNA sequencing, site-directed mutagenesis, and sequence 
analysis 
The plpE gene was cloned by immunoscreening a P. haemolytica 
expression library (described above) with affinity purified · anti-45 kDa 
antibodies according to the manufacturer's· instructions. Additional DNA 
cloning was performed as described previously (Pandher and Murphy, 1996). 
Site-directed mutagenesis was performed using the Gene Editor™ in vitro 
Mutagenesis System (Promega Corp., Madison, Wis.). Mutations were 
confirmed by DNA sequence analysis. Plasmid inserts were progressively 
deleted from both ends using the Erase A Base kit (Promega), and 
progressively smaller plasmid inserts were sequenced using the universal 
and reverse primers. Both DNA strands were sequenced. DNA sequencing 
was performed at the OSU Recombinant DNA/Protein Resource Facility, on 
an Applied Biosystems (Foster City, Calif.) 373A automated DNA sequencer. 
Sequences were analyzed with MacVector/ Assemblylign (Oxford Molecular 
Group, Inc., Campbell, Calif.). The deduced amino acid sequence of PlpE was 
compared with other sequences in GenBank using BLAST 2.0 (Altschul et al., 
1997), and alignments were generated with CLUSTALW 1.7 at the Baylor 
College of Medicine Search Launcher. 
Antigen preparation and western immunoblots .. 
Whole cell lysates were prepared and western immunoblots were 
performed as described previously (Pandher and Murphy, 1996) (Dabo et al., 
1994). Primary antibodies used for each western immunoblot experiment are 
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described in the Results section. Alkaline phosphatase-conjugated mouse 
monoclonal, anti-bovine IgG, (Sigma Immunochemicals, St. Louis, Mo.), 
(1:20,000) in TSGT, was always used as the secondary antibody in western 
immunoblots. 
[ 3H]-Palmitic acid labeling of bacterial lipoproteins 
Labeling and analysis of logarithmic-phase P. haemolytica, non-
recombinant E. coli, and recombinant E. coli that express PlpE, were 
performed using [9, 10-3H]-palmitic acid (Dupont, NEN, Boston, Mass.) as 
described previously (Dabo et al., 1994). 
Absorption of immune serum with intact cells 
Bovine immune serum was absorbed with intact P. haemolytica using a 
modification of a previously described method (Hansen et al., 1988). 
Logarithmic phase P. haemolytica, from one liter of culture (A600 of 0.5), were 
pelleted by centrifugation, washed once in PBS, and resuspended in immune 
serum diluted 1:100 in Tris-saline-nonfat dry milk (TSM, 10mM Tris pH 7.4, 
0.9% (w /v) NaCl, 1 % non fat dried milk). Cells resuspended in serum were 
incubated at 4°C for 3 hrs on a rocking platform. Following incubation, cells 
· were pelleted by centrifugation at 11,000 x g. The supernatant was carefully 
removed and stored at -20°C following the addition of sodium azide at 0.02%. 
Unabsorbed immune serum was used as control and was diluted 1:100 in 
TSM before use. Absorption with recombinant E. coli (pB4522) and non-
recombinant E. coli (pBluescript SK-) was performed similarly except 
stationary phase organisms were used. 
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Complement-mediated killing assay 
Serum from a calf with a low ELISA antibody titer against P. haemolytica 
was used as a complement source. The complement-source serum was 
depleted of any existing antibodies against P. haemolytica by incubation with 
excess, stationary phase P. haemolytica, at 4°C, on a rocking platform, for 1 hr. 
Before incubation with complement-source serum, P. haemolytica were 
washed once with cold PBS (4°C). 
Serum from an OMP-vaccinated calf (described above) was used as the 
source of antibodies. The antibody-source serum was heat-inactivated at 56 °C 
for 30 min (to inactivate compliment) and was used in two different forms: 
(1) Anti-PlpE antibodies were removed from antibody-source serum by 
adsorbing the serum with recombinant E.coli expressing PlpE. This process 
would also adsorb out any anti-E. coli antibodies that were present in the 
serum. (2) Therefore a control serum from which only anti-E. coli antibodies 
were removed and was prepared by adsorbing the antibody-source serum 
with non-recombinant E. coli (pBluescript SK-) (Stratagene, La Jolla, CA, 
USA). Adsorption of serum with recombinant and non-recombinant E. coli 
was performed as follows. Recombinant and non-recombinant E. coli were 
grown overnight in 100ml of Luria broth (GIBCO-BRL, New York, USA) and 
harvested by centrifugation at 4 °C. The cells were washed once with PBS and· 
subsequently used to adsorb out antibodies from antibody-source serum that 
had been diluted 1:1 with PBS. Two ml of this diluted antibody-source serum 
was incubated with recombinant E. coli, at 4°C for 3 hrs, on a rocking 
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platform (# 1). At the same time another 2 ml of diluted antibody-source 
serum was also incubated with non-recombinant E. coli (# 2). After 
incubation, cells were removed from serum by centrifugation. This process 
was repeated until the serum incubated with recombinant E.coli, did not 
recognize PlpE in a western immunoblot (data not shown). 
The complement-mediated killing assay was developed by modifying the 
techniques described by Chae et al. (Chae et al., 1990) and Murphy et al. 
(Murphy et al., 1986). To ensure that the assay was capable of detecting a 
change in the amount of bactericidal antibody, numbers of bacteria and 
concentration of complement were evaluated in preliminary experiments 
(Murphy et al., 1986). For complement-mediated killing assays, bacteria were 
grown in BHI broth for 18 hours at 37°C, on a rotary shaker (200 rpm). Cells 
were washed once with PBS and resuspended in PBS to an A6oo of 0.5. 
Complement-source serum (50 µl) and antibody-source serum (#1 or #2 
described above) (50 µl) were added to 150 µl of PBS. P. haemolytica (9000-
18,000 du in 40 µl PBS) were then added. Immediately after the addition of P. 
haemolytica (t = 0) and after incubating for 30 min in a 370c water bath (t = 
30), 100 µl samples were removed and diluted 1:100 in PBS. Dilutions were 
prepared and plated on BHI agar plates for determination of du. At t = 30, 
undiluted reaction mix was also plated for determining du. To monitor the 
killing activity of the complement-source serum alone, a control with only 
complement-source serum and no antibody-source serum was evaluated in 
an identical manner. We also determined that the antibody-source serum 
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alone had no killing activity (data not shown). Percent killing was calculated 
by the following formula: {(CFUt = O - CFUt=30) I CFUt=O} 100. Percent 
survival was calculated as 100-percent killing. 
Statistical.analysis 
Complement-mediated killing assays were done in triplicate for each 
antibody source serum and the complement-source serum control. Three 
separate experiments were done on different days. Statistically significant 
differences between killing by antibody.:.source sera 1 and 2 were determined 
within experiments by Student's t test (Bailey, 1981). 
Results 
Cloning of plpE 
To isolate a clone expressing the immunogenic 45 kDa protein, we 
screened a genomic library of P. haemolytica 51 with anti-45 kDa antibodies 
that were affinity purified from bovine immune serum. We isolated 
recombinant lambda ZAPII phage that reacted with the affinity-purified 
antibodies. A recombinant plasmid containing a 4.5 kbp insert was excised. 
from one phage clone and transformed into E. coli (XLl-Blue). We subcloned 
a 2.2 kbp fragment from this insert into pBluescript SK(-) and named this 
plasmid pB4522. E. coli (pB4522) expressed a 45 kDa protein that was 
recognized by the affinity purified antibodies (Fig. 11a). We named this 
protein PlpE. 
Surface exposure of PlpE. As mentioned in the Introduction, we 
previously demonstrated the presence of an immunogenic 45 kDa P .. 
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haemolytica protein that is surface exposed (chapter 1). To determine if PlpE 
expressed by the recombinant E. coli strain, corresponds to the strongly 
immunogenic P. haemolytica surface protein, we examined surface exposure 
of the protein on intact P. haemolytica. Adsorption of bovine immune 
serum with intact P. haemolytica resulted in a loss of antibody reactivity on 
western immunoblots with recombinant PlpE and a protein of the same Mr 
in P. haemolytica whole cell lysates (Fig. lla, b), suggesting that PlpE is 
surface-exposed in P. haemolytica. Similarly, absorption of the same bovine 
immune sera with intact recombinant E. coli (pB4522) expressing PlpE 
resulted in a loss of reactivity to rPlpE and to a 45 kDa protein in P. 
haemolytica (Fig. llc, d). These data suggest that PlpE is also exposed on the . 
surface of recombinant E. coli and that PlpE is the primary 45 kDa surface-
exposed immunogen of P. haemolytica. 
Sequence analysis of PlpE. DNA sequencing of the cloned insert in pB4522 
revealed an open reading frame of 1064 nucleotides that begins with a GTG 
codon and encodes a protein with a calculated molecular weight (MW) of 39.1 
kDa (Fig. 12). The deduced amino acid sequence contains a putative 
hydrophobic signal peptide followed by a consensus lipoprotein processing 
site (LSAC) (Fig. 12). The calculated MW of the putative mature form of PlpE 
is 37.03 kDa. The N-terminal region of the putative mature PlpE contains 
eight copies of a six amino acid repeat (Fig. 12) that are predicted to form a 
hydrophilic domain (Fig. 13). PlpE also has numerous other hydrophilic 
domains that correspond with regions of high surface probability (Fig. 13). A 
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search of GenBank sequences and subsequent sequence alignments revealed 
that the deduced amino acid sequence of PlpE has 18% identity and 32% 
similarity to an outer membrane lipoprotein (OmlA) produced by 
Actinobacillus pleuropneumoniae serotype 1 and 20% identity and 35% 
similarity to the OmlA protein from A. pleuropneumoniae serotype 5 (Fig. 
14). 
Site-directed mutagenesis of the putative GTG start codon. To verify that 
GTG functions as a translational start codon for PlpE, we performed site-
directed . · mutagenesis and converted the codon to GGG. Western 
immunoblots of whole cell lysates from the wild-type and mutant E. coli 
(pB4522) strains, probed with anti-45 kDa antibodies, revealed that the mutant 
strain no longer produced a 45 kDa immunoreactive protein, suggesting that 
GTG functions as the translational start codon (Fig. 15). 
Lip~d Modification of PlpE. Because the deduced amino acid sequence· 
contained a consensus lipoprotein processing site, we examined P. 
haemolytica and E. coli (pB4522) for the presence of 45 kDa lipid-modified 
proteins. P. haemolytica, E. coli (pB4522), and non-recombinant E. coli 
(pBluescript) were grown in the presence of 3H-palmitic acid. A 45 kDa, 3H-
labeled lipoprotein is present in whole cell lysates of P. haemolytica and E. 
coli (pB4522) but absent from the non-recombinant E. coli strain (Fig. 16). 
Conservation of PlpE among serotypes of P. haemolytica. To determine if 
PlpE is expressed by other P. haemolytica serotypes, we examined whole cell 
lysates of P. haemolytica serotypes 1, 2, 5, 6, 7, 8, 9, 11, 12, 13, 14, and an 
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untypeable strain of P. haemolytica, by western immunoblot analysis, for 
reactivity with the anti-45 kDa antibodies (Fig. 17). The antibodies recognized 
a 45 kDa protein in serotypes 1, 5, 6, 7, 8, 12, and 14, an approximately 35 kDa 
protein in serotypes 2 artd 13, and a ,...;65 kDa protein in serotype 9 and the 
untypeable strain. The purified antibodies did not recognize a protein in the 
serotype 11 strain. 
Role of anti-PlpE antibodies in complement-mediated · killing of P. 
haemolytica. We sought to determine if anti-PlpE antibodies contribute to 
complement-mediated killing .of P. haemolytica. Since we had observed that 
E. coli (pB4522) have the .capacity to remove anti-PlpE antibodies from bovine 
serum, we used the recombinant strairi to deplete those antibodies from 
bovine immune serum .. We then compared complement-mediated killing of 
P. haemolytica using,, as an antibody source, bovine immune serum or 
immune serum depleted of anti-PlpE antibodies. As shown in Fig 18, 
immune serum that was .depleted of anti-PlpE antibodies caused less killing 
of P. haemolytica than did immune serum that was not depleted of those 
. antibodies. . The difference in killing activity was statistically significant 
(p<0.003). 
Discussion 
We have cloned, sequenced, and analyzed an immunogenic lipoprotein 
(PlpE) of P. haemolytica. In our previous studies, we had noted an intense 
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i~munogenic band at 45 kDa level, in western blots of P. haemolytica OMPs · 
(sarkosyl insoluble fraction), probed with sera from immune cattle (data not 
shown). Our studies directed at identifying surface-exposed OMPs of P. 
haemolytica revealed that. this immunogen at 45 kDa is surface-exposed 
(chapter 1). We hypothesized that antibodies against the surface-exposed 
regions of this protein . are important in host defense mechanisms such · as 
complement-mediated killing. 
Although PlpE migrates to 45 kDa level on an SDS polyacrylamide gel, we 
found that the calculated molecular weight of the deduced amino acid 
sequence of the mature form of this protein is 37 kDa. This discrepancy could. 
. . . 
possibly be due to the fact that PlpE is rich in proline (5.93%), a turn inducing 
amino acid residue that causes the protein to migrate slower on SDS-PAGE 
(Postle, 1990). Analysis of the deduced amino acid sequence of PlpE revealed a. 
positively charged amino terminal region, a central hydrophobic region 
followed by a consensus lipoprotein processing site LSAC (Hayashi and Wu, 
1990). We were able to prove lipid modification of PlpE by 3H-palmitate 
labeling of the mature form of PlpE in recombinant E. coli (pB4522). The N-
,: . . 
terminal region of the protei~ is composed of _ eight copies of 6 amino acid· 
repeats. We noted four of these to be exact copies while the other four 
contain substitutions with similar amino acid residues. It might be of interest 
to study these repeats in different strains of P. haemolytica in order to 
determine their candidacy as a site of antigenic variation. 
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A data base search revealed that PlpE is similar to an Actinobacillus 
pleuropneumoniae lipoprotein OmlA. Gerlach et al. (Gerlach et al., 1993) 
have demonstrated that vaccination of pigs with purified OmlA from 
serotype 1, significantly reduces lung damage and death of pigs upon 
subsequent experimental challenge with homologous A. pleuropneumoniae 
serotype. 
Western immunoblot analysis revealed that antibodies reactive against · 
PlpE from P. haemolytica serotype A . 1 recognize proteins of similar 
molecular weight in serotypes 5, 6, 7~ 8, and 14. These antibodies recognize a 
protein of -65 kDa in serotype 9 and. an untypeable strain of P. haemolytica 
and a proteins around 35 kDa in serotypes 2 arid 13. Thus PlpE could be a · 
significant cross-protective antigen making . it a favorable candidate· for 
inclusion into a sub~unit vaccine. 
Another interesting feature of the gene plpE is that it utilizes GUG as a 
translational start codon .. GUG, AUG, and UUG fall in the group of class I 
initiation codons that support efficient translation (Sussman et al., 1996). In 
E. coli the intrinsic activity of GUG is 12-15% of AUG (Ringquist et al., 1992). 
About 8% of known bacterial genes from E.coli and other organisms utilize 
GUG as the start codon (Schneider et al., 1986). To our knowledge plpE is the 
first example of a P. haemolytica gene utilizing GUG as a start codon. 
From our previous studies it was unclear as to how many proteins 
contributed towards the major immunogenic band seen at 45 kDa.level in 
western blots of P. haemolytica probed with bovine immune serum. Our 
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surface-exposure studies on PlpE helped answer that question. Absorption of 
bovine immune serum with intact recombinant E. coli (pB4522) virtually 
abolished the reactivity of this serum at 45 kDa level of P. haemolytica whole . 
cell lysates. This result indicates that PlpE is the major immunogen 
responsible for the significant, immunogenic band at 45 kDa level. Further, 
the ability of intact recombinant E. coli (pB4522) to absorb out anti-PlpE 
. antibodies suggest that the signal peptide of PlpE is functional in E. coli so that 
PlpE is trafficked to the E. coli cell membrane and is. exposed on the cell 
surface. The surface-exposure of recombinant PlpE and its ability to absorb 
out anti-PlpE ·. antibodies suggests .· that recombinant PlpE assumes . a 
·· conformation quite similar to the native form in P. haemolytica. Hence, 
recombinant E. coli (pB4522) could be used in vaccination trials to deliver •. 
PlpE in a folded, membrane associated form that resembles dosely, if not 
completely, the native P. haemolytica form. 
According to our hypothesis, antibodies directed against surface'-exposed 
epitopes of PlpE should help in opsonization of P. haemolytica and aid in 
host defense mechanismE; like complement-mediated ,killing and 
. ' . . . 
phagocytosis by neutrophils and macrophages. We were able to demonstrate 
that depletion of antibodies against surface-exposed epitopes of PlpE, by· 
absorption of immune serum with intact recombinant E. coli (pB4522), 
caused a significant reduction in complement-mediated killing of P. 
haemolytica. Our negative controls that had compliment source alone and 
no source of antibody failed to kill P. haemolytica (we actually saw growth) .. 
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These data suggest that complement activation through the alternative 
pathway does not play any significant role in the killing of the organism. 
This result is congruent with a previous study that demonstrated that the . 
classical pathway is the only complement cascade important in killing of P. 
haemolytica (MacDonald et al., 1983). 
The serum used as antibody source in complement-mediated killing assay · 
. . 
was collected on .day 36, after three immunizations with P. haemolytica OMPs -
(sarkosyl-insoluble fraction). Therefore, we expect IgG to be the predominant 
circulating isotype and to be _ the - predominant isotype _ involved in 
complement-mediated killing. Although IgM is the_ most potent activator of 
the classical complement cascade, its concentration in circulation is relatively 
low in an anamnestic immune response. This observation has in vivo 
relevance. Most beef cattle develop a titer to P. haemolytica early in their life -
and continue to encounter P. haemolytica through natural exposure (Frank, 
1985) and vaccination. Hence, it can be assumed that P. haemolytica infection 
of the lung encounters a secondary immune response, which consists of IgG 
as the predominant • circulatory antibody. The role _ of IgM-mediated killing 
mechanisms in this scenario should be rather minimal. In addition, Mosier 
et al., 1989, found that anti-P. haemolytica IgM antibodies did not seem to play 
a major role in development of -resistance to experimental pneumonic 
pasteurellosis. 
This study has demonstrated that PlpE is a significant immunogen of P. 
haemolytica and that antibodies against this protein aids complement-
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mediated killing and presumably other antibody-dependent host defense 
rnechanisrns. Our data justify the use of PlpE as an experimental vaccine to 
study the protection it rnay confer to cattle against experimental P. 
haemolytica challenge. We believe that PlpE is a strong candidate as a 
component of a sub-unit vaccine developed to induce irnrnunity against P. 
haemolytica infection. 
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Fig. 11 
Western immunoblots demonstrating surface exposure of PlpE in P. 
haemolytica and in recombinant E. coli. Lanes: Whole cell lysates of (1) P. 
haemolytica; (2) E. coli (pB4522) expressing PlpE; (3) non-recombinant E. coli 
(pBluescript SK-). Blots were probed with (a) bovine immune serum, (b) 
immune serum absorbed with P. haemolytica, (c) immune serum absorbed 
with non-recombinant E. coli (pBluescript), and (d) immune serum absorbed 
with E. coli (pB4522). 
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The nucleotide sequence of plpE and the deduced amino acid sequence of 
PlpE. Sequences corresponding to E. coli consensus -35, -10 and ribosome 
binding sites (SD seq.) sites, 5' of the gene, are underlined. The consensus 
lipoprotein processing site is underlined with a dashed line. The eight 
imperfect, hydrophilic repeats in the amino terminal region of PlpE are also 
underlined. 
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1 AGGGCTAATCTACTACAGCCCCAAAAATTTTCATAAGGGAAACGTTTACGTAAAACTCCT 60 
-35 -10 
61 CAGACCACTCATTCTTATTTTATATAAAAAATGTGATAGACTTCTCGCAGTTTCGTTTTA 120 
SD seq. 
121 TATATTTAAGGAATAACTAAGTGAAATTCAATAAAAAATTAATTTTAACATTTGCTGCAA 180 
1 V K F N K K L I L T F A A 13 
181 CCTTAGTTTTAAGTGCTTGCGGAGGAAGCGGTAGCGGAGGTTCGTCTTCAACACCGAATC 240 
14 T L V L s A C G G s G s G G s s s T p N 33 
241 ACCCCAAACCAGTACTAGTACCAAAAACACAAAATAATCTTCAAGCACAAAATGTTCCTC 300 
34 H p K p V L V p K T Q N N L Q A Q N V p 53 
301 AGGCACAAAATGCCTCTCAGGCACAAAATGCCCCTCAGGCACAAAATGCTCCTCAGGCAC 360 
54 Q A Q N A s Q A Q N A p Q A Q N A p Q A 73 
361 AAAATGCTCCTCAGGTGGAAAATGCTCCTCAGGCACAAAATGCTCCTCAGGTAGAAAATG 420 
74 Q N A p Q V E N A p Q A Q N A p Q V E N 93 
421 CTCCTCAAGCAGAGGTTACTCCGCCTGTACCACAGCCACAATCACAAAAAATTGACGGTT 480 
94 A p Q A E V T p p V p Q p Q s Q K I D G 113 
481 CTTTTGATAAAATTGGTTCAGTAAAACTCAATAAAGAGGCTCAAACTCTTGAGCTTAGTA 540 
114 s F D K I G s V K L N K E A Q T L E L s 133 
541 GATTCACTTTGGTGGATAAATTAGGCACACCACCGAAGTTTGATAAAGTAAGCGGTAAAA 600 
134 R F T L V D K L G T p p K F D K V s G K 153 
601 AAATTATTGAAGAAAAAGATTTTCTCGTATTAAATTTGTCTGATATTAATGCTGAACAAC 660 
154 K I I E E K D F L V L N L s D I N A E Q 173 
661 TCTCTGGCGATTTTCTTATTCGCCGTAGCGATGATCTATTCTATGGCTACTATCACGATA 720 
174 L s G D F L I R R s D D L F y G y y H D 193 
721 CAAATGGCAAAAATCTTGTCGATGCTGCCGATAAATTCAGTCAATATTTTGTCGTGTATG 780 
194 T N G K N L V D A A D K F s Q y F V V y 213 
781 ATGAGAAACGGGTAAATGATAATATCTCTGATAAATTAACAGCAACTTACCGTAAAAAAG 840 
214 D E K R V N D N I s D K L T A T y R K K 233 
841 AAGGCTTTGTATATGGTTCAAATCCACATACTAAAGAATTTGCCGCACGGATCAGCAAAT 900 
234 E G F V y G s N p H T K E F A A R I s K 253 
901 TGGGGGATGTAGAAATTAAATTTGAAAATGGTCAAGCTCAAGGAAGTATAAAAGACGAAA 960 
254 L G D V E I K F E N G Q A Q G s I K D E 273 
961 AAGATGGAAATGCTGAGATCTTTACTATTAAAGGTGATACAAAACAGTTAGAGATTACCC 1020 
274 K D G N A E I F T I K G D T K Q L E I T 293 
1021 CAACGGAAAGTAACCGAATCATTATAGCAATTTTAGACCAAAATCAAAAAAGCTATACTC 1080 
394 p T E s N R I I I A I L D Q N Q K s y T 313 
1081 CAGGAATGGAAAAAGCAATTATGGAAACTAAGTTTATTGATTCAAAGGCTGGTAATTCCG 1140 
314 p G M E K A I M E T K F I D s K A G N s 333 
1141 ACCAAAAATACTTAATCGGTGAAGCAAAAAGCGATAACTGGCAAGCAATAATGGTTAGCG 1200 
334 D Q K y L I G E A K s D N w Q A I M V s 353 
1201 AGAAAAAATAAAGTTATCTTTTGCTAAAAACTGAAATAAAAAGGCTGAGTCCGGGTAATA 1260 
354 E K K 356 
1261 TCGGCCTCAGTCTTTTAAATTGTAGAAAATCATCTGTAGAAGATCAAACC 1310 
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Fig. 13 
Hydrophilicity plot of the deduced amino acid sequence. of PlpE. The 
hydrophobic signal peptide and the · hydrophilic, hexapeptide repeats . are 
indicated. Positive valu~s represent .. hydrophilic regions. The plot was 
generated using the Kyte-Doolittle algorithm in MacVector, with a window 
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Fig. 14 
Alignment of the deduced amino acid sequences of PlpE and OmlA 
proteins from A. pleuropneumoniae serotypes 1 (OmlAl) · and 5 (OmlAS) .. 
• .. 
The amino acids residues of OmlAl and OmlAS that are identical to PlpE 
have been capitalized. 
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1 15 16 30 31 45 46 60 61 75 76 90 
1 OmlAl mniatKLmaslvAsv VLtACsGgGSsGSSS kPNseltpkVdmsap kaeqpkkeevpAdn skaeepkemAPQvd- sPkaEepknmapqmg 89 
2 Om1A5 mniatKLiaglvAgL VLtACsGgGSsGSSp kPNsestpkVdmsap kaeqpkkeeApAds pkaekpksiAPlmme nPkVEkqkennlqek 90 
3 PlpE vkfnkKLiltfaAtL VLsACgGsGSgGSSS tPNhpkpvlVpktqn nlqaqnvpqAqAsq aqnapqaqnAPQaqn aPqVEnapqaqnapq 90 
91 105 106 120 121 135 136 150 151 165 166 180 
1 OmlAl npklndpqVmaPkmd nPQkdapKgeelskd ksnaeilKElgvkdi nSgiinnadvvlnlK iDekdhitvvldKgk inrNhlkvtntisaq 179 
2 Om1A5 spkAdepqVmdPklg aPQkddQKleep-kn ksnaeilKElgikdi tsgtisisdielnlq lDsndnvKisllnen LmrdnltINnkiags 179 
3 PlpE venApqaeVtpPvp- qPQ--sQKidgsfdk igsvklnKEaqtlel -SrftlvdklgtppK fDkvsgkKiieeKdf LvlNlsdINaeqlsg 176 
181 195 196 210 211 225 226 240 241 255 256 270 
1 Oml.Al DiktlkdSsgkllgy YGYmqlnqvrqdeny sD-ekvslneYylls mNDadkirpTksisy KgdmfYsykdvgnqk lkAsveasyDdvtKk 268 00 
2 Om1A5 DirtlkdSsgrllgy YGYvqlnqvtqdsrd pDnykhqFenhylls mNDaekilpeksley KgsmiYGyNtsgnek ltAevnakyDsstKk 269 ('r) -3 PlpE Dflirr-Sdd---lf YGYyhdtngknlvda aDkfsqyFvvYdekr vNDnisdklTatyrk KegfvYGsNp-htke faArisklgDveiKf 261 
271 285 286 300 301 315 316 330 331 345 346 360 
1 OmlAl vsmkvfGenndywKl Gefgrtn--llenQv tgakvgedgtIIngt Lyskidnfplkltpd anfsggifgKnG--- -evLaGsAiSek--W 350 
2 OmlA5 lsmkvyd-ndrywKl Gevmsnnvrlpeekv dgvkvdSdg-tinar Lylste-eplkltpd anfsggifgKnG--- -evLaGkAeSikgeW 352 
3 PlpE engqaqG-sikdeKd GnaeiftikgdtkQl eitpteSnr-IIiai Ldqnqksytpgmeka imetkfidsKaGnsd qkyLiGeAkSdn--W 347 
361 375 
1 OmlAl QgvigatattkedKK 365 
2 OmlA5 QgvigatattkedKK 367 
3 PlpE Qa-Imvse-----KK 356 
Fig. 15 
Western immunoblot demonstrating the effect of mutagenesis of the GTG 
. . . 
codon on production of PlpE. The blot was probed with affinity purified anti-
45 kDa antibodies. Lahes: 1, E. coli (pB4522) with GTG and expressing PlpE; 2, 




PlpE ...... _,_ 
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Fig. 16 
Autoradiograph of SDS-polyacrylamide gel of 3H-palmitate-labeled total 
cellular proteins. Lanes: 1, P. haemolytica; 2, E. coli (pB4522) expressing PlpE; 






Western immunoblot of whole cell lysates of P. haemolytica serotypes 1, 2, 
5, 6, 7, 8, 9, 11, 12, 13, 14, and an untypeable strain, probed with anti-45 kDa 
antibodies. The lane numbers represent the serotypes with UT representing 
the untypeable strain. 
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Fig. 18 
Complement-mediated killing activity of anti-OMP bovine immune 
serum. Serum used as source of antibodies: A, bovine immune serum 
absorbed with E.coli (pB4522); B; bovine immune serum absorbed with non-
recombinant E. coli (pBluescript SK-); C, complement· source alone without 
' ' 
· anti-OMP serum .. Values greater than 100% represent growth. Data shown 
are the mean and standard deviation of three replicates from a single 
experiment and are representative of the separate experiments. The 
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